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The most beautiful thing we can experience is the mysterious. It is the source of all 
true art and science. 
 
Albert Einstein 
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Summary 
Cardiovascular disease is the leading cause of mortality in the developed countries 
and platelet related thrombosis the main complication in this condition. Anti-platelet 
agents are commonly used in the prevention of acute cardiovascular events. 
According to the American Heart Association and the American College of 
Cardiology (Circulation 2012), a class IIb recommendation is given for the use of 
platelet function test. This approach has been implemented in several clinical trials in 
order to improve outcomes in cardiovascular patients [1]. There are a number of 
platelet function tests available for clinical use but there is a lack of correlation 
between the different tests and none of them are routinely used to assess anti-platelet 
therapy effect. We report a rapid and accurate methodology to quantify platelet-
protein interactions termed iPA. This novel technique contains a micro-array of 6-μm 
fibrinogen dots which can capture platelets from whole blood, one platelet per dot. 
The fractional occupancy of an array of fibrinogen dots after a predefined incubation 
time (specifically 30 minutes) quantitatively assays platelet adhesion to the protein 
matrix. We demonstrated that iPA enables detection of the effects of aspirin, P2Y12 
inhibitors and αIIbβ3 receptor inhibitors in vitro. The mechanism of iPA to detect the 
effectiveness of anti-platelet therapy is based on a decrease of platelet adhesion upon 
addition of an agonist. An important factor to note regarding iPA is that in 
comparison to a fibrinogen coated array, the profile of platelet adhesion is different. 
On a static fibrinogen coated array platelet agonists would normally increase 
adhesion and spreading due to an increase in platelet activation. However the same is 
not true for iPA. Platelet activation induces aggregation and the aggregates thus are 
unable to bind during the assay. The reasoning behind these events is that firstly iPA 
is performed on a rocker, thus not allowing platelet aggregates to adhere 
gravitationally. Secondly the size of the dot is optimized to capture a single platelet. 
13 
 
This agonist induced decrease in adhesion is inhibited by the specific anti-platelet 
drug and this is in fact the mechanism of detection.  
To summarise, in iPA normal resting platelets adhere maximally. Platelets that are in 
the presence of a platelet inhibitor also adhere normally to the 6-μm fibrinogen dots. 
Platelets stimulated with agonists show a marked reduction in fibrinogen occupancy. 
Platelets in the presence of antagonists and agonists show an occupancy value that is 
dependent on the effectiveness of the anti-platelet agent over the agonist.  
Furthermore we showed that iPA can specifically detect the effect of each drug in 
patients treated with these anti-platelet agents. iPA correlated well with the standard 
techniques of flow cytometry and light transmission aggregometry. Furthermore, iPA 
can be easily integrated with microfluidic platforms.   
Overall it promises to be more effective and rapid in the assessment of drug effects 
of anti-platelet agents during the treatment of cardiovascular disease. 
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Schematic representation of platelet adhesion in the novel assay iPA. The novel 
assay enables detection of anti-platelets drug effect. In this picture we show how iPA 
can detect cangrelor when ADP is added. ADP induces aggregation and these 
aggregates do not bind to the 6µm fibrinogen dots. In samples with cangrelor, ADP 
does not induce aggregation and platelets adhere to the fibrinogen array.  
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Chapter 1  
Introduction 
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1.1 Platelet function 
Human platelets were first observed in blood films by Donné in 1842 using 
microscopy [2]. However, it was not until 1882 that Bizzozero demonstrated that 
platelets were essential in thrombosis and haemostasis [3]. Since then platelets have 
been shown to be involved in other processes including inflammation, host defence 
and even tumour growth and metastasis. Platelet function research has increased 
dramatically, especially over the last three or four decades. Knowledge on platelet 
function, their receptors and signal transduction pathways has expanded in parallel 
with the technological advances in science. 
Human platelets stem from megakaryocytes in the bone marrow and their average 
lifespan is 7 – 10 days. They patrol the vasculature checking for and repairing sites 
of vascular damage, circulating at concentrations of 150-450 10
9
 cells/L. Their shape 
and small size (2 to 5 µm diameter) causes the platelets to be pushed to the 
surrounding edge of the vessels during flow, placing them in the prime location 
required to arrest bleeding and repair damage of the vasculature (haemostasis). 
Our understanding of platelet function and their role in disease has increased since 
their discovery, but so has the morbidity rate in platelet related diseases. 
Cardiovascular diseases are the main causes of death in the developed world [4, 5]. 
Coronary artery disease itself is the single most common cause of mortality in this 
group of disorders [6]. Coronary artery disease involves the accumulation of 
arteriosclerotic plaque (cholesterol, fat etc.) on the walls of the coronary arteries. 
This atherosclerotic plaque can detach from the vessel wall and withdraw the 
surrounding endothelial cells causing exposure of a highly thrombotic matrix 
comprised of collagen and von Willebrand factor (vWF) [4, 7]. This thrombotic 
matrix can capture platelets resulting in pathological arterial thrombosis which, if 
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occlusive, stops the blood flow. Thrombosis of the coronary arteries can block the 
blood supply to the heart causing myocardial infarction and death.  
The platelet adhesive protein fibrinogen becomes rapidly localized at a site of 
vascular lesion by adsorption from plasma and it polymerises to form insoluble 
fibrin [8]. Platelets can interact with fibrinogen/fibrin on the vessel wall under 
conditions of low shear stress through the integrin αIIbβ3 [9]. This interaction, like 
that of vWF with GP Ib-IX-V, does not require platelet agonists, a feature that may 
enable the initiation of platelets binding to vascular injury [10].  
The role of platelets in thrombosis and haemostasis can be defined by the main 
functional events; adhesion, secretion, formation and stabilisation of the thrombus. 
Following adhesion platelets spread, form a monolayer and platelet become activated 
[11]. Then platelets release agonists such as ADP and thromboxane which enhances 
platelet activation and stable adhesion to fibrinogen, fibronectin and vWF. Integrin 
αIIbβ3 activation is also a key mechanism for platelet aggregation and thrombus 
formation. The presence of platelet agonists in the surrounding environment, and the 
involvement of the coagulation cascade in enzyme activation of thrombin and fibrin 
formation are events that drive toward a stable, irreversible thrombus. Fibrinogen-
αIIbβ3 interaction plays a pivotal role in platelet function and is the main subject in 
this thesis. Specifically platelet adhesion to immobilised fibrinogen has been chosen 
to study platelet function. 
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1.2 Fibrinogen structure, immobilization and conformational changes 
Fibrinogen is a highly abundant plasma protein that circulates in the blood at a 
concentration of approximately 3mg/ml. As a glycoprotein, it is comprised of 
three pairs of polypeptide chains called Aα, Bβ and γ [12], linked together by 
disulfide bonds. Its structure consists of a symmetrical dimer with dimensions 
of approximately 45 x 4.5 x 4.5 nm. Fibrinogen has three hydrophobic globular 
domains, two outer D domains, and a single E domain in the centre of the 
molecule connected by alpha-helical coiled-coil rods of the α, β and γ chains. 
The secondary structure of fibrinogen comprises of α-helix, β-sheet and β–turn 
domains [13]. Each fibrinogen Aα chain contains an N-terminal fibrinopeptide 
A (FPA) sequence, that is cleaved by thrombin in the initiation of fibrin 
formation [14, 15]. When thrombin cleaves the FPA sequence, it exposes the 
polymerization site EA in the E domain of the fibrinogen molecule. Each EA-
site binds to a complementary sequence in the γ-chain of the D domain of the 
neighbouring fibrinogen molecule. Fibrinogen polymerization starts and 
double-stranded fibrils form through end-to-middle domain (D:E) associations. 
Then concomitant lateral fibrils associate creating a clot network. Fibrin 
assembly facilitates intermolecular antiparallel C-terminal alignment of 
gamma-chain pairs, which are then covalently 'cross-linked' by factor XIII 
('plasma protransglutaminase') to form 'gamma-dimers' [12]. It has been shown 
in vitro that in both arterial and venous thrombus a fraction of fibrinogen is 
converted to insoluble fibrin and the rest remains as fibrinogen or fibrinogen 
fragments [16, 17]. Arterial and venous thrombosis are considered two 
different disorders as a result of the obvious anatomic and clinical 
presentations. Arterial thrombus is related to platelet activation whereas 
venous thrombus is a matter of activation of the clotting system. Nevertheless 
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there is evidence suggesting similarities between both pathologies. For 
example fibrin formation which is characteristic of venous thrombosis, has 
also been described in the left atrial appendage of patients with atrial 
fibrillation and in the coronary artery system of patients with myocardial 
infarction (Prandoni, 2009, Clin.Epidemiology). 
 
 
Figure 1.1 Schematic diagram of fibrinogen structure. Fibrinogen has three 
globular domains, two D domains and one E domain. The three globular domains are 
connected by the coiled-coil regions of the α, β and γ chains. In the α chain, the 
fibrinopeptide A (FPA) sequence is cleaved by thrombin in the initiation of fibrin 
formation. Furthermore there is a fibrinopeptide B (FPB) in the Bβ chain which is 
also cleaved by thrombin. The transglutaminase, factor XIII, mediates covalent cross 
links between the γ chains of two fibrinogen molecules. 
 
Immobilised fibrinogen can be found in many physiological and pathological 
conditions. Using radioimmunoassays and electron microscopy, several investigators 
have shown the presence of fibrinogen and fibrin in the arterial sub-endothelium and 
tunica intima, the innermost layer of an artery or vein [18]. Fibrinogen and fibrin 
also accumulate in atherosclerotic plaques and surrounding cells of the vessel wall 
(smooth muscle cells and macrophages) [19-21]. Synthetic materials such as 
vascular prostheses or dialysis membranes also adsorb fibrinogen from blood [13, 
22, 23]. It has been postulated that the conformation of fibrinogen changes when it is 
immobilised by adsorption on a surface [24-26]. This hypothesis is supported by the 
E domain 
D domain 
γ chain 
411aa 
D domain 
FPB 
Factor XIII 
FPA 
Coiled coils of the α, 
β and γ chains 
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fact that resting unactivated platelets adhere to immobilised fibrinogen but not to 
fibrinogen in solution. This implies that adsorption induces a conformational change 
in fibrinogen that exposes binding sites recognizable by resting platelets. To further 
understand this conformational change of immobilised fibrinogen, circular dichroism 
spectropolarimetry was used to quantify changes in the secondary structure of 
fibrinogen [25]. It was found that the adsorption of fibrinogen to a broad range of 
surfaces induces the loss of α helices in its secondary structure. This structural 
change leads to protein unfolding and the exposure of platelet binding sites in the 
fibrinogen molecule. It has also been shown using atomic force microscopy that 
fibrinogen unfolds and unravels following immobilization [27, 28]. These changes in 
the secondary structure of fibrinogen and the subsequent exposure of hidden binding 
sites may explain how immobilised fibrinogen is able to bind unactivated platelets. 
Interestingly it has been shown that the loss of the α helical secondary structure 
during unfolding from fibrinogen correlates strongly with platelet adhesion (r
2
=0.96) 
[27]. It has been found that when fibrinogen adsorbs to either hydrophilic or 
hydrophobic surfaces it is able to elongate up to 5 times its original length, further 
suggesting that immobilization of the molecule induces unfolding and exposure of 
platelet binding sites [29].  
Fibrinogen contains three platelet interaction sites, two of which are located in the 
centre of the molecule; the sequence (RGDF) at Aα95–98 and the sequence (RGDS) at 
Aα572–575 [30]. The third platelet binding domain, the dodecapeptide sequence 
(HHLGGAKQAGDV) is located in the distal end at γ400–411 [31, 32]. It is not fully 
understood how these sequences contribute to integrin αIIbβ3 mediated platelet 
adhesion [33], but the carboxy-terminal γ chain dodecapeptide has been shown to be 
involved in mediating adhesion of non-stimulated platelets to immobilised 
fibrinogen [34].  
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When fibrinogen is immobilised on an artificial surface, it can be orientated in two 
ways; side on or end on [35]. In the side on orientation, fibrinogen can bind 
irreversibly to a surface through the D domains and the middle E domain and 
become positioned horizontally on the surface. In the end on orientation, fibrinogen 
can bind reversibly to a surface through its D domain only, leaving the immobilised 
fibrinogen in a vertical position. Both orientations reveal sites able to bind platelets.   
Platelets bind to fibrinogen through integrin αIIbβ3, the most abundant receptor on 
the platelet surface [36, 37]. Nevertheless there are many other receptors in platelets 
and some of them will be described in this thesis. 
 
1.3 Platelet agonists and receptors  
Platelet receptors are essential for the recruitment of circulating platelets at sites of 
vascular injury as well as for the subsequent platelet activation and their aggregation 
[38]. The most important platelet receptors are glycoproteins and G protein-coupled 
receptors. Glycoproteins are proteins that contain oligosaccharide chains (glycans) 
covalently attached to polypeptide side-chains. Receptors involved in platelet 
recruitment, adhesion and aggregation are glycoproteins which are listed below. 
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Table 1.3.1: Glycoproteins: Receptors involved in platelet recruitment, adhesion 
and aggregation. 
 
 
Family 
 
Glycoprotein 
 
Cluster 
Differentiation 
antigen (CD) 
 
Ligand 
 
Leucine-rich 
repeat 
 
Complex GPIb-IX-V 
Ib 
IX 
 
 
42b 
42a 
 
vWF 
Ig 
Superfamily 
GPVI 32A Collagen 
 
 
Integrins 
 
GPIaIIa (α2β1) 
Ia 
IIa 
 
49b 
29 
Collagen 
α5 
β1 
49e 
29 
Fibronectin 
αV 
β3 
51 
61 
Vitronectin, 
fibrinogen, vWF 
GPIIbIIIa (αIIbβ3) 
IIb 
IIIa 
 
41 
61 
Fibrinogen 
 
The vWF receptor, GPIb-IX-V and the collagen receptor, GPVI are glycoproteins. 
But the most important glycoproteins in platelets are large membrane spanning 
heterodimers proteins known as the integrins. They are comprised of two subunits, α 
and β, which are non-covalently linked and can be subdivided into a cytoplasmic, a 
transmembrane and an extracellular region [39]. α2β1 (GPIa-IIa) is a platelet integrin 
which is the major collagen adhesion receptor on platelets and a wide range of other 
cells. The most abundant integrin in platelets is the integrin αIIbβ3 (GPIIb-IIIa 
complex). This receptor is specific for platelets and is essential for platelet – platelet 
binding during aggregation and thrombus formation. Moreover this integrin is 
important in platelet adhesion to damaged surfaces by having the capacity to bind to 
vWF.  
The other type of platelet receptors, G protein-coupled receptors (GPCRs) are also 
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known as seven transmembrane receptors and are listed below.  
Table 1.3.2: Platelet Receptors G protein-coupled receptors. Receptors of the 
amplification phase. 
 
Family Receptor Ligand 
G protein-
coupled 
receptors 
 
 
P2Y1 ADP 
P2Y12 ADP 
PAR1 Thrombin (high 
affinity) 
PAR4 Thrombin (low 
affinity) 
Thromboxane 
receptors TP 
Thromboxane 
 
As already mentioned platelet adhesion and aggregation at the site of vascular injury 
is mediated by glycoproteins. Following adhesion platelet become activated event 
that is known as amplification phase. Throughout the amplification phase or second 
phase of the thrombus formation, platelets become activated and new platelets are 
recruited to the growing platelet plug. G protein-coupled receptors are involved in 
platelet activation during the amplification phase. G protein-coupled receptors are 
divided in P2 purinergic receptors, thromboxane receptors and PAR receptors, which 
recognise ADP, thromboxane and thrombin respectively.  
Most research carried out in this thesis focuses on platelet adhesion to immobilised 
fibrinogen through αIIbβ3. However, the P2 purinergic receptors, its agonist ADP 
and its specific antagonists; cangrelor / clopidogrel are also studied. Both ADP and 
fibrinogen stimulate platelet responses during thrombosis, however their mechanism 
of activation is entirely different. ADP acts through the platelet signalling pathway 
known as “inside – out signalling” while fibrinogen stimulates a signalling pathway 
known as “outside – in signalling”. The overall outcome of ADP activation is to send 
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signals into the platelet, stimulate shape change and ultimately convert αIIbβ3 from 
its resting conformation into an active ligand binding state. Following αIIbβ3 
activation, soluble fibrinogen binds to the receptor. Fibrinogen is a multimeric 
protein, with multiple binding sites for αIIbβ3 per molecule; fibrinogen is thus able 
to link several platelets to each other. P2Y receptors, αIIbβ3 and the thromboxane 
receptor function and their agonists are explained in more detail below. 
αIIbβ3 (GPIIb-IIIa complex): αIIbβ3 is the receptor for fibrinogen, fibronectin, 
vitronectin and vWF and is expressed uniquely on platelets with 50,000 to 80,000 
copies per platelet. Plasma fibrinogen binds to activated platelets, facilitating platelet 
aggregation, a critical step in thrombus formation [40]. This is only possible when 
αIIbβ3 is in a high affinity, ligand binding state. In its low affinity state, the α and β 
subunits are connected to each other at their cytoplasmic, transmembrane and 
extracellular regions. The fact that both tail regions are associated with each other 
keeps the cytoplasmic region bound. Upon agonist stimulation, the α and β tail 
dissociate and the receptor changes into its active state. However, immobilised 
fibrinogen does not require αIIbβ3 to be in its high affinity state, and hence resting 
un-activated platelets can bind to immobilised fibrinogen [10]. Nevertheless it has 
been shown that the adhesion of platelets to immobilised fibrinogen does increase 
when platelets are activated [41, 42]. Paradoxically, it has also been shown that 
inhibitors such as prostaglandin E1 (PGE1), theophylline, apyrase or protease 
inhibitors do not affect platelet adhesion to solid phase fibrinogen [10, 43]. 
αIIbβ3 has been a main target of research for anti-platelet drugs used in the treatment 
of coronary artery diseases. Molecules and antibodies which bind and block αIIbβ3 
are commercially available and include abciximab, eptifibatide and tirofiban.  
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These are routinely used before percutaneous coronary intervention (PCI) to prevent 
the formation of platelet thrombi in the heart. Eptifibatide and tirofiban are also 
indicated to prevent platelet mediated thrombosis in non-ST elevated acute coronary 
syndrome patients [44]. 
P2Y12: P2Y12 belongs to the Gi family of the G protein-coupled receptors and it is 
found mainly but not exclusively on platelets and together with P2Y1 comprised the 
receptors for ADP [45]. ADP is stored in platelet dense granules and is released only 
after platelet activation [46]. Platelet activation by ADP can be autocrine, when ADP 
originates from the same platelet and paracrine when ADP is secreted by a near cell. 
When platelets secrete dense granules a secondary platelet response is generated 
[47]. In brief ADP binding to P2Y12 regulates adenylyl cyclases and 
phosphatidylinositol 3-kinases [48, 49]. This generates inside-out signalling and 
activation of αIIbβ3 thus inducing platelet aggregation and secretion. Even though 
ADP is a weak agonist, the blockage of the P2Y12 receptor significantly affects 
platelet function and P2Y12 inhibitors are commonly used for the treatment of 
coronary artery disease. These can be explained by the fact that P2Y12 is mainly 
found on platelets and not in other cells. Clopidogrel, prasugrel, ticagrelor, cangrelor, 
ticlopidine, and elinogrel are all P2Y12 inhibitors with clopidogrel being one of the 
best selling drugs world-wide. 
P2Y1 
The P2Y1 receptor is widely distributed in many tissues including central nervous 
system and blood platelets [50]. About 150 P2Y1 receptor binding sites are expressed 
per platelet [38]. P2Y1 receptor activates the Ga q/phospholipase C pathway leading 
to generation of second messengers like inositol tris-phosphate (IP3) and 
diacylglycerol (DAG) [51]. IP3 mobilizes calcium from the intracellular stores while 
DAG activates the protein kinase C isoforms. This activation leads to platelet shape 
26 
 
change [52], and contributes to ADP-mediated platelet aggregation and thromboxane 
A2 generation [53]. 
Thromboxane receptor, thromboxane prostanoid (TP): The thromboxane receptors 
belong to the Gq and G12/13 families of the G-protein coupled receptors. Upon 
platelet activation endogenous Arachidonic acid (AA) is cleaved from the 
phospholipid membrane in platelets and metabolised to eicosanoid. This process is 
mediated by both phospholipase A2 and C [54] which has been shown to be calcium 
dependent [55]. AA is then converted to thromboxane A2 (TxA2) by the enzyme 
cyclooxygenase-1 (COX-1) TXA2 is then released into the extracellular space, where 
it binds to its TP receptor and thus activates platelets [56]. TXA2 binding to G13 
receptors has been shown to regulate Rho-kinase mediated pathways and induce 
platelet shape changes. When TXA2 binds to Gq receptors there is activation of 
phospholipase C (PLC) which results in formation of IP3 and diacyl glycerol leading 
to an elevation of free cytoplasmic [Ca
2+
] and activation of protein kinase C (PKC), 
respectively [47]. The most commonly used anti-platelet drug, aspirin, blocks the 
COX-1 pathway and thereby inhibits synthesis of TXA2. 
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Figure 1.3: A schematic representation of a platelet and its receptors.  
The platelet receptors for vWF, collagen and fibrin(ogen) are shown in this image. 
The most common platelet G protein-coupled receptors and their specific agonist are 
illustrated along with sites of action for their antagonist. Some intracellular functions 
related to these receptors are also depicted.  
 
 
1.4 Anti-platelet therapies; Aspirin, P2Y12 inhibitors and αIIbβ3 inhibitors 
Platelet activation is a major complication in patients with acute coronary syndrome 
and can cause adverse cardiovascular events [57, 58], one of the major causes of 
morbidity and mortality in the western world [4]. As a result anti-platelet therapy is 
one of the cornerstones in the prevention and treatment of coronary artery disease. 
Clinical trials have demonstrated the benefit of aspirin, P2Y12 inhibitors and αIIbβ3 
inhibitors in the management of patients with acute coronary syndrome [59]. 
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Aspirin: Aspirin enters the platelet by diffusion through the plasmatic membrane and 
irreversibly acetylates serine 529 of the cyclooxygenase (COX1) resulting in 
inhibition of thromboxane A2 generation by platelets and prostacyclin by endothelial 
cells [60]. While the biosynthesis of thromboxane A2 is practically abrogated by low 
concentration of aspirin the inhibition of prostacyclin biosynthesis depends on the 
aspirin dose. High aspirin dose (325 mg) has been shown to decrease prostacyclin 
biosynthesis up to fifty percent of the pre-treatment levels [61]. Aspirin is the most 
widely used therapy for the treatment and prevention of coronary artery diseases [62, 
63]. In spite of this, approximately 15-25 % of patients have recurrent clinical events 
while on aspirin [60]. Such a circumstance has been called by some authors “aspirin 
resistance” but this term can be misleading and it is better described by “treatment 
failure” or “clinical resistance”. On the other hand it has been found that in some 
patients aspirin failed to inhibit thromboxane synthesis and reduce platelet 
aggregation [64], some patients are therefore aspirin non-responders. There has been 
considerable interest in aspirin non responsiveness which has led to development of 
new platelet function tests to measure response to anti-platelet drugs. The platelet 
function test used to asses aspirin non-response varies among groups [65] and there 
has been little agreement between the results of each assay [66, 67]. The prevalence 
of aspirin non response has varied considerable between studies from 5 to 60 % [68] 
this is due to the variable results of different platelet function test and the lack of 
agreement on the laboratory definition of aspirin response. Several mechanisms for 
aspirin non-response has been proposed; poor patient compliance, inadequate aspirin 
dose, platelet COX-1 independent thromboxane production [64] and particularly 
increased in platelet turnover [68, 69].  
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ADP: ADP receptor antagonists are commonly used in combination with aspirin to 
reduce the risk of recurrent major adverse cardiovascular events. Clopidogrel is the 
most commonly used ADP receptor antagonist which irreversibly binds to and 
blocks the P2Y12 receptor [45]. Clopidogrel has to be metabolized by cytochrome 
P450 in order to become active. P450 metabolism depends on both clinical and 
genetic factors [70] and certain P450 polymorphisms have been associated with poor 
drug efficacy [71]. Patients with high residual platelet reactivity even after 
clopidogrel treatment show higher risk of cardiovascular events (myocardial 
infarction and stroke) [72]. To note, it has been reported that 4-46% patients have 
high (on clopidogrel treatment) platelet reactivity [72, 73]. What is more, clopidogrel 
pharmacodynamics are affected by other medications, such as proton pump 
inhibitors (PPI). These drugs are used to treat gastrointestinal bleeding in patients on 
long term medication; however they do reduce the anti-platelet activity of 
clopidogrel by 50% [74].  
The new ADP receptor antagonist prasugrel has been shown to be more potent than 
clopidogrel at platelet inhibition but has shown a higher level of clinically significant 
bleeding [75]. In addition, it has been shown that the risk of bleeding associated with 
prasugrel increases when it is prescribed in combination with other anti-platelet 
drugs [76]. 
αIIbβ3: αIIbβ3 inhibitors have also been shown to be beneficial for patients with 
acute coronary syndrome [59]. αIIbβ3 inhibitors such as abciximab, tirofiban and 
eptifibatide can be used for the treatment of unstable angina or before percutaneous 
coronary intervention (PCI). The disadvantage of these drugs is that the high level of 
receptor blockade required to achieve a potent antithrombotic effect significantly 
undermines haemostasis, resulting in an increased risk of bleeding. This indicates a 
narrow therapeutic index of αIIbβ3 inhibitors which has also been described in ADP 
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receptor inhibitors. Therefore both under and over medication of αIIbβ3 and ADP 
receptor inhibitors have been shown to be harmful for patients [77].  
To conclude, the highly variable response to anti-platelets drugs in patients and the 
narrow therapeutic index of ADP receptor and αIIbβ3 inhibitors indicate an 
increasing need to monitor anti-platelet therapy in patients with cardiovascular 
disease in order to provide the best personalized therapy to each patient and avoid 
adverse events. 
 
1.5 Current platelet function tests 
There are a number of platelet function tests available for clinical use. However there 
is a lack of correlation between different tests and none of them are routinely used to 
assess anti-platelet therapy effect [78]. These tests measure different parameters of 
platelet function which include bleeding or clotting time, platelet aggregation, 
platelet adhesion, platelet granule release, the expression of platelet activation 
markers and the viscoelastic properties of a platelet clot. The gold standard technique 
for platelet function testing is light transmission platelet aggregometry (LTA). There 
are also point-of-care (POC) aggregometry-based tests which have the advantage of 
using whole blood and being user friendly. These include ICHOR-Plateletworks
®
 
and VerifyNow
®
 but they are not routinely used. ICHOR-Plateletworks
®
 
measurement is highly time dependent, should be performed within 10 min from 
blood sampling and does not predict adverse cardiovascular outcomes [79]. 
VerifyNow
®
 is the most expensive point-of-care test on the market (45 euro/ 
cartridge) and is not flexible as it can only measure one anti-platelet drug at the time 
using 2 ml of blood per sample [80]. VerifyNow
®
 has also been shown to have a 
limited dynamic range, with reduced sensitivity at higher levels of anti-platelet drug-
induced inhibition [81].  
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Surprisingly, there are few reports of platelet function assays based on adhesion to 
specific proteins, despite the fact that platelet adhesion is the initiating event in 
haemostasis and thrombus formation [4]. The few adhesion assays that are available, 
such as IMPACT-R, have poor accuracy in detecting the activity or efficacy of anti-
platelet drugs [82] and do not predict cardiovascular outcomes [83]. 
The ideal methodology to measure platelet function and the response to anti-platelet 
drugs would enable quantitative measurement of a physiologically relevant 
parameter, such as platelet adhesion to specific proteins, closely linked to platelet 
function and to the status of particular classes of platelet receptors. This assay would 
be performed directly in whole blood within a short time after a blood draw. 
 
1.5.1 Bleeding time 
This test simply involves making a small incision in the skin and then touching a 
piece of filter paper onto the edge of the bleeding wound at standardised time 
intervals until bleeding stops. Nowadays the use of bleeding time is not considered 
to be a useful platelet function test since it is time consuming, relatively invasive and 
has poor reproducibility. In addition bleeding time can be influenced by a wide range 
of variables, including skin temperature, skin thickness, haematocrit and von 
Willebrand factor levels [84]. Bleeding time is a poor indicator of bleeding risk and 
it is incapable of predicting cardiovascular events [85]. 
 
1.5.2. Serum thromboxane (TXB2) 
TXA2 is an agonist released by platelet upon activation and has a half-life of 
approximately 30 seconds, which makes it difficult to measure. However TXA2 is 
converted to the more stable TXB2 which can be monitored using an enzyme 
immunoassay (ELISA) kit. For this assay 3-5ml of blood is drawn and transferred 
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into a sample tube. The sample is then incubated at 37°C for 30-60 minutes during 
which time a clot forms. The serum is then removed and placed into 96 well plates 
containing specific TXB2 antibodies. The output is TXB2 concentration which 
reflects the inhibition of cyclooxygenase enzyme (COX). COX enzyme converts AA 
into TXA2 but is irreversibly inhibited by aspirin [86]. Therefore the measurement of 
TXB2 indirectly reflects aspirin responsiveness and has been extensively used [87, 
88]. 
The major advantage of measuring serum TXB2 is that it does not have to be 
measured immediately and clinical samples can be frozen at -20°C and stored to be 
analysed later if necessary. However this assay is relatively time consuming, requires 
expertise, tests only a single pathway within platelets and is quite expensive. 
 
1.5.3 Light transmission aggregometry 
Light transmission aggregometry (LTA) was first described by Born in 1962 and is 
probably the most widely used platelet function assay. The LTA assay uses platelet 
rich plasma (PRP) and light. Light passes through the stirred PRP and is scattered by 
the platelets, thus reducing the amount of light transmitted. Upon addition of an 
agonist to the PRP, platelets aggregate, reducing the light scattered and increasing 
light transmission. The greater the degree of platelet aggregation, the more light 
transmitted. LTA has been used to monitor the effect of anti-platelet agents such as 
aspirin, ADP inhibitors and αIIbβ3 inhibitors [89-92]. Breet et al. JAMA, 2010 have 
shown that LTA can predict future cardiovascular events. LTA was measured in 
patients undergoing coronary stent implantation and atherothrombotic events were 
recorded for one year. It was found that high on treatment platelet aggregation was 
associated with adverse cardiovascular events [83, 93]. 
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The major advantage of LTA is that it can be used to test multiple agonists thus 
providing valuable information on multiple signalling pathways. On the other hand 
LTA has major limitations which explain why there has been such an interest in 
development of new platelet function tests. LTA is time consuming, requires 
relatively large amount of blood and expertise. In addition, by using PRP instead of 
whole blood, LTA is less physiological than other platelet function tests. 
 
1.5.4 Whole blood aggregometry 
Whole blood aggregometry (WBA) is similar to LTA but instead uses whole blood. 
It was first described in 1980 by Cardinal and is more physiological than LTA [94]. 
This method measures the change in electrical impedance or resistance between two 
electrodes following stimulation with a platelet agonist. Anti-coagulated blood 
samples are diluted with saline in a 1:1 ratio, placed in a cuvette and stirred at 37°C. 
The platelets adhere to the electrodes when they aggregate causing an increase in the 
impedance between the two electrodes. The change in impedance is then converted 
to percentage of aggregation. The whole blood aggregometer is not only more 
physiological than LTA but requires less blood manipulation thus decreasing the risk 
of platelet pre-activation. On the other hand, WBA requires larger volumes of 
agonists than LTA and surprisingly, there have been conflicting reports on how well 
LTA correlates with WBA [95, 96]. Nevertheless WBA has been used to evaluate 
aspirin and clopidogrel responsiveness in both healthy volunteers and in patients 
with cardiovascular diseases [97]. 
 
1.5.5 Microtiter plate (MTP) 
This is an aggregation based high-throughput assay with the ability to measure up to 
96 samples simultaneously. A small volume of platelet rich plasma or wash platelets 
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are placed in a 96-well plate together with a platelet agonist and/or antagonist. 
During the run time, the plate is incubated at 37 °C and shaken. The absorbance 
values used to measure the platelet response decreases while platelets aggregate [98]. 
This technique has been shown to have greater sensitivity than light transmission 
aggregometry to detect the potency of the agonist [99]. What is more, this assay can 
be used ex vivo to identify high platelet reactivity [100]. Similarly to LTA, this assay 
is time consuming, requires qualify personal and relatively large amount of blood.  
 
1.5.6 VerifyNow
®
 
The VerifyNow
® 
is also a whole blood aggregometer but it is a real point-of-care 
device. Citrated whole blood is inserted into the VerifyNow
® 
device and the blood is 
then drawn into a mixing chamber which contains lyophilised fibrinogen-coated 
beads and a platelet agonist. A steel ball is then used to agitate and mix the sample 
using an electromagnet. The sample is positioned between a light source and 
detector. The agonist triggers aggregation resulting in an increase in light 
transmission. There are three different cartridges which can measure the effect of 
aspirin, P2Y12 and αIIbβ3 inhibition separately. In the cartridge used to measure 
aspirin the agonist of choice is AA (1mmol/L) and the results are expressed as 
Aspirin Reaction Units (ARU). The cut-off value for non-response to aspirin is ≥ 
550. In the cartridge used to test P2Y12 there are two chambers.  The first contains 
thrombin receptor-activating peptide (TRAP). Given that TRAP is such a potent 
agonist it induces platelet aggregation even in the presence of inhibitors. This 
chamber provides a maximum measurement of platelet function and allows the 
percentage of P2Y12 inhibition to be calculated. The second chamber contains both 
ADP (20µM) and prostaglandin E1 (PGE1) at 22 µM. The PGE1 is used to suppress 
the platelet activation contribution from ADP through the P2Y1 receptor, therefore 
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making the assay more P2Y12 specific. For this cartridge the results are expressed as 
P2Y12 Reaction Units (PRU). Finally there is also a cartridge for measuring αIIbβ3 
antagonism. This cartridge contains TRAP and the results are expressed in Platelet 
Aggregation Units (PAU). VerifyNow
®
 has been used in several studies to 
investigate the correlation with LTA but the data is conflicting. Some studies have 
demonstrated excellent correlation between LTA and VerifyNow
®
 using AA [101, 
102] whereas other studies have shown that the agreement between the two assays is 
poor [103]. 
 
1.5.7 Thromboelastograph
® 
(TEG) 
The thromboelastograph (TEG) was first described by Hartert in 1951 [104]. In this 
assay whole blood is incubated in a heated rotating sample cup. As the blood clots 
the cup’s motion is reduced by the strengthening clot. The assay uses heparin as an 
anticoagulant to eliminate thrombin activity in the sample. Reptilase and factor XIIIa 
(activator F) are used to generate a cross-linked fibrin clot to isolate the fibrin 
contribution to the clot strength. The addition of AA or ADP to the assay has 
enabled TEG to be used to monitor anti-platelet therapy [105]. Nevertheless TEG 
has been shown to correlate weakly with AA-induced aggregation by LTA [93, 106, 
107]. 
The main advantage of TEG is that is a whole blood, point-of-care assay, however, 
there are only few studies showing correlation between TEG and cardiovascular 
outcomes [108]. 
 
1.5.8 IMPACT cone and a plate(let)analyzer 
The cone and plate(let)analyzer was described by Varon and colleagues in 1997. 
Since then the original method has been developed into an automated device called 
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IMPACT (Image analysis, Monitoring, Platelet, Adhesion, Cone & Plate 
Technology). 
This device tests platelet function in anti-coagulated whole blood using laminar flow 
and physiologically relevant arterial conditions. 130 µl of whole blood is placed in a 
polystyrene well and a shear rate of 1800 sec
-1
 is applied for 2 minutes. Blood 
proteins immediately adhere to the well surface and become available for platelets, 
resulting in platelet adhesion and aggregation to the wells. Following washing of 
excess blood and staining of the adhered platelets, quantification of the adhesion is 
performed by the built-in image analyzer. The results are expressed as percentage of 
the well surface coverage. Platelet surface coverage (percentage SC) represents 
platelet adhesion and average aggregate size (AS in µm
2
) represents platelet 
aggregation. The addition of ADP and AA to the test enables detection of anti-
platelet drugs. The agonists are pre-incubated with whole blood at concentrations of 
1.38 μM for ADP and 0.32 mM for AA for 1 minute under gentle mixing (10 RPM) 
prior to the IMPACT test. This leads to platelet activation and micro-aggregate 
formation in the tube resulting in reduced platelet adhesion as reflected by a reduced 
SC. As previously mentioned this test is not very accurate in the measurement of 
anti-platelet medication [82] and does not predict cardiovascular events [83]. 
 
1.5.9 Platelet ATP/ADP secretion test 
This assay of platelet function enables measurement of platelet degranulation by 
calculating the amount of ATP/ADP released by platelets [109]. When platelets are 
activated the contents of their intracellular granules (ADP, ATP, fibrinogen etc) are 
secreted, an event termed degranulation. Washed platelets (70µl) are placed in a 96-
well plate and incubated at 37° for 10 min with/without the agonist/antagonist. The 
plate is placed on a plateshaker for described times. The detection reagent Chrono-
37 
 
lume (which luminesses when bound to ATP/ADP) is subsequently added to each 
well. Luminescence is then measured according to the ATP/ADP release. This assay 
has the advantage that it can be used to study a large number of samples 
simultaneously. Moreover, it is sensitive at detecting a range of agonist and 
antagonist potencies [110]. However it needs to be optimised to become a real point 
of care device since currently this test is time consuming and requires qualified 
personnel. 
 
1.6 Conclusion and rationale for developing of a novel platelet function assay based 
on adhesion to fibrinogen microdots 
It is well established that platelets are involved in the development of thrombosis; 
therefore anti-platelet medications like aspirin and clopidogrel are routinely used to 
prevent cardiovascular events related to platelet mediated thrombosis. However there 
is a highly variable response to anti-platelet drugs in patients, especially to the P2Y12 
inhibitor clopidogrel. Moreover ADP and αIIbβ3 receptor inhibitors have been 
shown to have a narrow therapeutic index [77]. Therefore it has been suggested that 
anti-platelet drug treatment should be monitored. There are a number of techniques 
that can measure platelet function, but most of them measure aggregation and not 
adhesion. There is also a lack of correlation between different tests and none of them 
are routinely used to assess the effect of anti-platelet therapeutics [78]. As mentioned 
before, platelet adhesion is one of the first steps in thrombosis and haemostasis.  
Since there is no agreement concerning the best approach to measure anti-platelet 
drugs we have develop a new assay, termed individual platelet adhesion (iPA) that 
measures both adhesion and aggregation. In this thesis we present iPA as a proof of 
concept for detection anti-platelet drugs.  
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Fibrinogen is the most abundant thrombogenic protein in blood and its receptor the 
integrin αIIbβ3 is the most abundantly expressed receptor on platelet surfaces. The 
ligands for αIIbβ3 in vivo are fibrinogen and vWF and according to Savage et al. 
Cell, 1996, platelets do adhere to immobilised fibrinogen under flow (shear rates 
below 600-900 s
-1
) and this interaction is via αIIbβ3. Therefore αIIbβ3 – fibrinogen 
interaction is one of the most important processes in platelet function and platelet 
adhesion to fibrinogen would be an ideal target for developing platelet function tests. 
In this thesis we describe a highly accurate assay for platelet function iPA. The assay 
is based on a fibrinogen microdot array. We designed this array using microcontact 
printing, a novel technique which allows protein patterning on a glass surface [111]. 
The array used in this thesis measures approximately 1 cm
2
 and contains microdots 
of 6 μm in diameter. Each array has the capacity to capture more than 600,000 
platelets per cm
2
.  
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Chapter 2 
Materials and Methods 
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2.1 Reagents 
All reagents were purchased from Sigma (St. Louis, MO, USA) unless stated 
otherwise. Microscope cover slides (20 × 20 mm
2
) were purchased from Agar 
Scientific Ltd. (Essex, England). Anti-CD41 (clone P2) antibody was purchased 
from Immunotech (Marseilles, France). Goat anti-mouse IgG Alexa Fluor 488 was 
purchased from Invitrogen (Carlsbad, CA, USA). Human fibrinogen (95% clottable 
and plasminogen depleted) was purchased from Calbiochem (Merck, KGaA, 
Darmstadt, Germany). Arachidonic acid was purchased from Bio Data (Horsham, 
PA, USA). Abciximab (ReoPro
®
) was purchased from Centocor (Leiden, The 
Netherlands). PE labelled anti-GP-IX antibody was from BD Pharmigen (San Jose, 
CA, USA). Anti-fibrinogen-FITC was purchased from Immunsystem AB (Uppsala, 
Sweden). Bovine serum albumin (BSA) was conjugated with Cy3 dye. BSA-Cy3 
was purchased from ChemQuest Limited (Wilmslow, UK). Cangrelor was from The 
Medicines Company, Parsippany, NJ, USA. 
 
2.2 Ethics 
Ethical approval for blood donations was provided by Medical Research Ethics 
Committees of the Royal College of Surgeons in Ireland, Beaumont Hospital, 
Dublin, Ireland and St Vincent’s Hospital Dublin, Ireland. All the protocols 
complied with the Declaration of Helsinki on human experimentation. Informed 
consent was obtained from all patients prior to phlebotomy. 
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2.3 Blood Collection 
Venous blood was collected into a syringe containing 3.2% sodium citrate (10% 
vol/vol). Platelet counts were performed using a Sysmex
TM
 haematology analyser 
(Kobe, Japan). 
 
2.4 Light transmission aggregation 
Platelet aggregation responses were measured using a light transmission 
aggregometer (LTA) (BioData: Horsham, PA, USA). For the preparation of platelet 
rich plasma (PRP), whole blood was centrifuged at 200 x g for 10 minutes at room 
temperature (RT) and the top platelet-rich plasma layer was carefully collected. Then 
the remaining cells were centrifuged at 2000 x g for 10 minutes to obtain platelet 
poor plasma (PPP). Platelet rich plasma was incubated for 5 minutes at 37°C without 
stirring prior to the addition of agonists; Adenosine diphosphate (ADP, 20µM) or 
AA (500μg/ml). Following initiation, each aggregation was monitored for up to 10 
minutes with 1200 rpm stirring with a stir bar. 
 
2.5 The novel platelet adhesion assay iPA 
2.5.1 Microcontact printing 
To develop an accurate platelet adhesion assay, a fibrinogen microdot array was 
generated using a previously described method [112]. To generate the fibrinogen 
microdot array we used silicon-based rubber stamps (Polydimethylsiloxane, PDMS) 
consisting of a micro array of pillars which transferred the protein onto a glass 
surface. These stamps were made up using a silicon master that also contains the 
micro-pattern. This master was generated at the beginning of the project and lasted 
over 4 years. Quality control steps for microcontact printing were not implemented 
because the novel assay iPA includes an internal control namely BSA-Cy3 which 
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will be explained later on in this thesis. Nevertheless quality controls steps should be 
implemented in the future for further development of this assay. 
 
Figure 2.5.1: Schematic representation of microcontact printing. a) For the 
master preparation a wafer thin silicon coated with a photoresist solution is irradiated 
with uv light through a photomask. The photoresist becomes stable upon irradiation 
with uv light. b) The master for microcontact printing consists of the stable areas of 
the photoresist. c) The PDMS solution is added to the master in combination with the 
elastomer and they are incubated at 80ºC for polymerization. Then the PDMS stamp 
is peeled and cut. d) The PDMS stamp is incubated with the fibrinogen and BSA-
Cy3 solution (15min at RT). e) The stamp is dried using nitrogen gas. f) The stamp 
is incubated on a glass slide for 5 min. g) The stamp is carefully peeled and the 
fibrinogen array is generated. 
 
2.5.1.1 Master for microcontact printing 
This work was carried out by Ana Lopez Alonso under the supervision of Prof. 
Lourdes Basabe-Desmonts. A wafer thin silicon disc approximately 10 cm in 
diameter was used. A Microposit S1818 positive photoresist solution was added to 
the surface of the silicon disc and spun at 5500 rpm for 30 seconds to allow solution 
to spread and cover total surface of the disc. Afterwards the disc was coated with 
Microposit S1818 it was cured for 1 minute in vacuum on a hot plate at 115°C. This 
Microposit S1818 positive photoresist solution is UV light sensitive and upon 
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irradiation with UV light the Microposit S1818 becomes a stable layer on the silicon 
disc. To generate the micro array on the master, the Microposit S1818 was irradiated 
with UV light through a photmask (Photronics, Mid Glamorgan, South Wales, U.K.) 
consisting of an micro array of opaque dots. Resultant features were developed by 
dipping the master in developer MF319 (Chestech Ltd,Warwickshire, U.K.) for 40 s 
and finally rinsing with water and drying under nitrogen. Subsequently, masters were 
exposed to a vapour of (tridecafluoro-1,1,2,2-tetrahydrooctyl)-1-trichlorosilane 
(Sigma-Aldrich Inc., Ireland) under vacuum for 1 h to facilitate the release of the 
PDMS mould after curing.  
 
2.5.1.2 Stamp preparation 
The master was then used to generate the stamps for microcontact printing. 
Polydimethylsiloxane (PDMS, Dow Corning Sylgard 184) was purchased from 
Farnell (Dublin, Ireland).) 60 ml of PDMS was mixed with the elastomer (10:1 
vol/vol PDMS/elastomer) and placed a vacuum chamber (bel-art® Desiccator 
Wayne, NJ 07470, USA) to eliminate bubbles. Then the master with the PDMS was 
placed in the incubator (Techne hybridiser HB-1D, Staffordshire, UK) at 80°C for 2 
hours or overnight. The PDMS was then carefully peeled from the master and cut in 
cubes of approximately 1cm
2
. 
 
2.5.1.3 Preparation of protein micro-array 
Protein micro dots were arrayed onto glass slides by microcontact printing. In brief, 
glass slides were rinse with ethanol and water and then dried. PDMS stamps were 
incubated with 100 µl of protein solution (200 μg/ml) in PBS for 15 min at RT. The 
stamps were dried using nitrogen gas and placed in contact with the previously 
rinsed slides for 5 min. Then the stamps were peeled and the slides were blocked 
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with 1 % BSA (10 mg/ml) for 1 h at RT. Protein arrays were shown to be stable for 
up to 2 weeks at 4°C in the dark. 
 
 2.5.2 Platelet capture by protein micro-array 
Single platelets were specifically captured by 6 µm in diameter protein (fibrinogen) 
dots as described by Basabe-Desmonts et al. To allow platelet adhesion, whole blood 
(1 ml) was added to the protein array and placed in a 35mm diameter Petri dish on a 
rocking platform, and incubated at 35 oscillations/minute at RT. The glass slides 
were washed with HEPES buffer ( 137 mMNaCl, 2.7 mMKCl, 1 mM MgCl2, 5.6 
mM glucose, 1 g/L BSA, 20 mM HEPES, pH 7.40) and then fixed with 3.7% 
paraformaldehyde (PFA). 
 
2.5.3 Immunolabelling 
For platelet staining, the glass slides were incubated with a primary mouse anti-
human CD41 antibody (1μg/ml) for 1 hour at RT. The slides were washed and then 
incubated with a secondary Alexa Fluor 488 (green) labelled goat anti-mouse IgG 
antibody (4μg/ml) for 20 min at RT in the dark. The slides were then rinsed in PBS 
and microscope images were taken from each sample.  
 
2.5.4 Imaging and software analysis 
The slides were imaged using a LSM510 UVMETA fluorescence microscope (Zeiss, 
Gӧttingen, Germany) or an inverted microscope (Olympus IX81) equipped with a 
xenon lamp as the light source. Images were collected with a 20 x objective. Alexa 
Fluor 488 labels were excited with light at 488 nm wavelength and Cy3 labels were 
excited at 543 nm.  
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2.5.5 Quantification of platelet adhesion by iPA 
Approximately 1000 fibrinogen dots were evaluated for each sample. Each image 
includes two colours: red for Cy3-BSA mixed with fibrinogen, which acts as a 
printing control, and green for platelets adhered to fibrinogen dots (Alexa Fluor 488-
labeled anti-CD41). Automatic quantification of the percentage of platelet-occupied 
fibrinogen dots was accomplished using a custom-designed computer program 
developed at the Biomedical Diagnostics Institute (Dublin, Ireland). This software 
enables protein dot quantification by colour coding. Platelet adhesion is calculated as 
the percentage of occupied dots (%), i.e., the number of green dots (bound platelets) 
divided by the number of red dots (total number of fibrinogen dots) multiplied by 
100%. This approach automatically corrects for any misprinted protein dots. 
Importantly, the binding of a single platelet on a single protein dot provides 
sufficient green fluorescence to unambiguously categorize the dot as platelet-
occupied. The red and green images were converted to binary images, after which 
particle analysis and BLOb (binary large object) analysis were carried out. The 
scripts used to calculate platelet binding were all coded in MATLAB 2008b 
(Mathworks, Natick, MA, USA). The process of extracting the dot array occupancy 
was divided into two separate processes: first, generating the fibrinogen “mask” (i.e., 
the locations of the fibrinogen plus BSA-Cy3 dots) and then extracting the number 
of platelets bound to the dots of the fibrinogen mask. To complete the analysis, a 
colour-coded image was generated displaying occupied dots (green), non-occupied 
dots (red), and platelets excluded from the calculations (grey). 
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Figure 2.5: Microscope image of: 
i        Protein array, 6µM dots BSA-Cy3 and Fibrinogen as printing control.  
ii       Platelets binding to protein array (CD-41-alexa 488).  
iii      Image software analysis - 70.8% Occupied dots.  
 
 
2.6 SDS Gel electrophoresis 
To assess the purity of the fibrinogen, a fibrinogen solution was prepared and 
separated by SDS page electrophoresis gel. A 7.5 % resolving gel was poured (3.5 
ml resolving buffer (0.375 M Tris-base, 0.4% SDS, pH 8.8 with HCl), 82 μl of 10% 
APS and 7.8 μl TEMED) and allowed to set for 45 minutes at room. The stacking gel 
was then poured (750 μl of 4X stacking buffer (0.5 M Tris, pH 6.8, 0.4% SDS), 500 
μl acrylamide/bis-acrylamide (29:1 ratio), 1.7 ml dH2O, 50 μl of 10% APS, 5 μl 
TEMED), and allowed to set 30 minutes. Sample buffer (125 mM Tris HCl, pH 6.7, 
3% SDS, 75 μg DTT, 20% glycerol, 0.05% bromophenol blue, 2 X stock) was added 
to the fibrinogen solution in a 1:1 ratio and heated to 95°C for 5 - 10 minutes. 
Samples were loaded onto the gels along with broad range (10 - 250 kDa) molecular 
weight markers. The gels were run in running buffer (25 mMTris, pH 8.8, 192 mM 
glycine, 0.1% SDS) at 80 Volts until the samples had run through the stacking gel, 
and then at 120 volts through the resolving gel. The gels were stained with 
Coomassie blue overnight at room temperature with continuous shaking. The gels 
were destained with destaining buffer (40% methanol, 10% acetic acid and 50% 
dH2O). The gels were then scanned using a Konica-Minolta C450.  
47 
 
2.7 Atomic Force Microscopy (AFM) 
To examine the fibrinogen array in more detail, atomic force microscopy (AFM) was 
used to assess fibrinogen spot size and height. This work was carried out in 
conjunction with Aurora Panzera at Dublin City University. As described previously, 
fibrinogen spots were arrayed on a glass coverslip by microcontact printing. The 
AFM was then operated in contact mode using a silicon nitride probe with a 
resonance frequency of 65 KHz and force constant 0.35 N/m.  
 
2.8 Measurement of platelet integrin αIIbβ3 levels by flow cytometry 
Platelet β3 expression was measured using the Biocytex Platelet Gp screen kit. The 
assay includes a primary unlabelled mouse anti-human antibody against the β3 
integrin and a secondary FITC-labelled anti-mouse IgG antibody. To measure β3 
levels, 20µl of diluted whole blood (1:4 dilution in kit buffer) was added to a flow 
cytometry tube and mixed with 20µl (10µg/ml) of anti-β3 antibody. The tubes were 
incubated for 10 minutes and then 20µl of polyclonal anti-mouse IgG-FITC was 
added. After 10 minutes, 2 ml of the kit buffer was added to stop the reaction. 
Samples were then analysed using a BD FACSCalibur (Becton Dickinson, Palo Alto, 
CA, USA). The instrument was set to measure size (forward scatter, FSC), 
granularity (side scatter, SSC) and cell fluorescence. Using a log FSC vs. log SSC 
dot plot, a two dimensional analysis gate was drawn around the platelet population, 
and a fluorescence histogram (log FL1 vs. count) was obtained for 10000 platelet 
events for each sample. The mean fluorescence intensity was obtained. Using this 
mean fluorescence intensity (MFI) value of each sample was used to calculate β3 
expression levels in reference to the MFI values of calibration beads with increasing 
known concentrations of immobilised mouse IgG. 
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Chapter 3 
 
Development and optimization of the new platelet adhesion 
assay iPA 
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3.1 Introduction 
The response to anti-platelet drugs is variable among cardiovascular patients. 
Moreover, high doses of platelet inhibitors could compromise haemostasis and be 
dangerous for the patients.  
Monitoring anti-platelet drugs can help to determine a patient’s response to the drug 
so to adjust and improve the treatment for each individual. There are a number of 
platelet function tests available for clinical use. However there is a lack of 
correlation between the different tests and none of them are routinely used to assess 
anti-platelet therapy effect [78].  
In our laboratory, we have developed a novel platelet function assay based on 
integrin αIIbβ3 mediated platelet adhesion to fibrinogen, namely iPA. Fibrinogen is 
the major physiological ligand for the platelet receptor integrin αIIbβ3, the most 
abundant receptor on the platelet surface. In suspension, fibrinogen facilitates 
platelet aggregation by crosslinking activated platelets, a critical step in thrombus 
formation in vivo. Furthermore, immobilised fibrinogen on the surface of activated 
platelets also acts as an adhesive substrate for platelet deposition during thrombus 
formation in vivo. The importance of the αIIbβ3 - fibrinogen interaction in 
haemostasis is highlighted by the bleeding phenotype associated with the congenital 
bleeding disorders Glanzmann thrombasthenia (a quantitative or qualitative defect in 
integrin αIIbβ3) and afibrinogenemia (decreased fibrinogen levels). In brief, iPA 
consists of 6 µm dots of fibrinogen arrayed on a glass coverslip by microcontact 
printing. This coverslip is incubated with whole blood under rocking conditions. The 
percentage of platelet adhesion is then calculated based on the number of occupied 
fibrinogen dots. In this chapter, we will detail the development and optimisation of 
this assay and show how it can be used to reliably monitor the effect of αIIbβ3 
receptor antagonists in vitro and ex vivo 
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Figure 3.1: Schematic representation of iPA: (i) The 6 µm fibrinogen array is 
incubated with whole blood for 30 minutes under rocking conditions. (ii) The 
platelets adhere to the fibrinogen array (iii) and then microscopic images are taken. 
(iv) the percentage of platelet adhesion is calculated based on the number of 
occupied fibrinogen dots using a computer program. 
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3.2 Results 
3.2.1 Whole blood versus PRP in iPA 
Although it has been verified that platelets can be captured from whole blood by iPA 
[112] we sought to determine if platelets from platelet rich plasma (PRP) would bind 
to the fibrinogen array in a similar manner. To examine this, whole blood from three 
healthy donors was collected and PRP was prepared (see materials and methods). 
Then the fibrinogen array was incubated separately with both whole blood and PRP 
following the methods previously described (section 2.5.2) for our novel assay. After 
platelets were labelled and images were taken in the three samples it was found that 
the percentage of platelet adhesion in samples containing whole blood was 59% [56, 
75] median [range]. However, in the PRP samples, aggregates where detected 
following application of iPA and quantification of adhered single platelets was not 
feasible (see Figure 3.2.1). Therefore we conclude that the iPA assay requires whole 
blood for accurate measurement of single platelets. 
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Figure 3.2.1: Platelet adhesion by iPA is unmeasurable when using PRP.  
Whole blood (i) and PRP (ii) was incubated with the fibrinogen array and platelets 
were captured, stained (anti-CD41) and images were taken (n=3). 
 
  
3.2.2 Fibrinogen array 
3.2.2.1 Purity of Fibrinogen  
The novel platelet adhesion assay is based upon platelets binding to a fibrinogen 
array. In order to verify that this assay was based purely on αIIbβ3-fibrinogen 
interaction and not αIIbβ3-vWF, we needed to test for purity of the fibrinogen 
solution used since it could contain traces of other platelet adhesive proteins such as 
fibronectin or vWF. Fibronectin and vWF impurities could affect levels of detection 
of anti-platelet drugs such as the fibrinogen receptor inhibitors since platelet could 
adhere to the array through the vWF (GPIb-IX-V) and fibronectin (α5β1) receptors. 
i) ii) 
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For this reason we performed a gel electrophoresis of the fibrinogen solution at two 
different concentrations. Under reducing conditions, fibrinogen separates into 3 
distinct bands representing the α, β and γ fibrinogen chains, at 70, 55 and 50 kDa 
respectively. Under reducing conditions vWF appears as one band at 240 kD and 
fibronectin appears at 200 kD. Upon separation, the fibrinogen solution used 
throughout this project was shown by Coomassie Blue staining to separate into three 
distinct bands at 75, 55 and 50 kDa. Moreover, gel staining revealed minor 
impurities that had different molecular weights than vWF or fibronectin. Since these 
impurities were different than those proteins which could interact with platelets at 
low shear (vWF and fibronectin) and because these impurities were practically 
negligible they were not identified (see Figure 3.2.2.1). 
 
Figure 3.2.2.1: SDS PAGE gel electrophoresis of fibrinogen solution. The purity 
of the fibrinogen solution used in this project was verified by SDS gel 
electrophoresis. It was shown that as expected for pure fibrinogen solution only three 
major bands at 75, 55 and 50 kDa were separated from our sample. 
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3.2.2.2 Fibrinogen concentration and type of solvent 
Microcontact printing is a technique used for protein immobilization and it has been 
used in this project for the preparation of the fibrinogen array. Microcontact printing 
uses a rubber stamp containing a micro-pattern which is incubated with the protein 
solution. Here microcontact printing of fibrinogen was further investigated and the 
optimal concentration and type of solvent were chosen. Fibrinogen was dissolved 
both in water and in phosphate buffer saline (PBS) at 50, 100, 150 and 200 µg/ml. It 
was found that fibrinogen did not fully dissolve in water as precipitates were 
observed. However fibrinogen entirely dissolved in PBS. The concentration of the 
fibrinogen solution used was 200µg/ml as lower fibrinogen concentrations did not 
fully cover the microcontact printing stamp probably due to hydrophobic 
interactions. Higher fibrinogen concentrations were not tested because ideally a low 
and more physiological fibrinogen concentration should be used. 
 
3.2.2.3 Verification of the size of the fibrinogen dots 
This is work published previously by our group (Basabe-Desmonts et al 2010) and it 
shows that 6 μm is the optimal fibrinogen dot size for capturing single platelets by 
iPA. 
                                   Fibrinogen dot size 
 
 
Figure 3.2.2.3.1: SDS Platelets (green) binding to fibrinogen dots of 12, 6 and 2 
µm in diameter. Maximal platelets occupancy was achieved by fibrinogen dots size 
6 µm and higher thus 6 µm dots were chosen for iPA. 
         12µm                            6µm                                2µm 
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Using atomic force microscopy (AFM), we assessed the fibrinogen spot size and 
spot height. AFM showed that the fibrinogen array was comprised of 5.4 ± 0.3 µm (n 
= 10) dots in diameter and the height of the dots were 11.25 ± 6 nm (mean ± SD, n = 
10). These 10 dots were created from the same master and the same stamp. 
A                                                                   B 
 
Figure 3.2.2.3.2: Atomic force microscopy images of 6 μm fibrinogen dots for 
quantification of the fibrinogen dots size. (A) AFM images of two 6 μm fibrinogen 
dots arrayed by microcontact printing. The fibrinogen dots were found to be on 
average, 5.4 ± 0.3 μm in diameter. The colour gradient bar gives an indication of the 
height of the fibrinogen dots, which was on average 11.25 ± 6 nm. (B) Graphical 
representation of the fibrinogen dot diameter and height. 
 
The dot height indicates the orientation of fibrinogen on a surface which can be end-
on side-on. 
 
Figure 3.2.2.3.3: Schematic representation of fibrinogen orientation. 
Fibrinogen height is 45 nm when in end-on orientation while in side-on 
orientation fibrinogen height is 9 nm. 
 
 
Fibrinogen molecule
Proc. Natl. Acad. Sci. USA Vol. 96, pp. 6705–6710, June 1999 Biophysics
End- on Side- on
45 nm
9 nm
Fibrinogen orientation
Langmuir 1992,8, 514-517
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Fibrinogen dots were found to be 11.2 ± 6 nm in height, n=10. The large SD (6nm) 
could be due to a non-homogeneous fibrinogen printing in side-on orientation. For 
example the fibrinogen molecules could be immobilised in one or two layers thus the 
height would be 9 nm for one fibrinogen layer and 18 nm for two fibrinogen layers. 
We do not know whether variable fibrinogen height (due to printing of several 
fibrinogen layers) will affect platelet adhesion thus this will have to be further 
examined for implication in quality control using several arrays from different 
stamps. 
 
3.2.2.4 Visualization of the fibrinogen dots using Cy3 labelled BSA 
In order to visualise the micro-array, the fibrinogen solution was mixed with Cy3 
labelled BSA in an 8 : 1 ratio (Fibrinogen : BSA). The labelled BSA acts as printing 
control, allowing validation of fibrinogen printing. By fluorescence microscopy, the 
fibrinogen dots appear red due to the Cy3 labelled BSA. Following platelet adhesion, 
the platelets are stained with an Alexa fluor 488 labelled anti CD41b antibody, 
giving the platelets a green colour by fluorescence microscopy. The use of 2 colour 
imaging allows the accurate calculation of the percentage of occupied dots (i.e.) the 
number of green dots (labelled platelets) divided by the number of red dots (printed 
fibrinogen dots) multiplied by 100%. During the optimisation of the assay, we 
assessed the effect of the addition of BSA-Cy3 to the fibrinogen solution on platelet 
adhesion to 6 μm dots. Fibrinogen arrays were prepared using fibrinogen solutions 
with and without Cy3 labelled BSA. Blood from three healthy donors was incubated 
for 30 minutes on these arrays and the percentage of occupied fibrinogen dots was 
calculated. The addition of Cy3 labelled BSA to the fibrinogen solution had no effect 
on platelet adhesion (Figure 3.2.2.4). The percentage of occupied dots was 46 %, 90 
% and 95 % in the three donors without Cy3 labelled BSA and 46 %, 93 % and 98 % 
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respectively with Cy3 labelled BSA. Therefore Cy3 labelled BSA was found to have 
no effect on platelet adhesion to fibrinogen.  
 
 
Figure 3.2.2.4: Cy3 labelled BSA mixed with fibrinogen has no effect on platelet 
adhesion to fibrinogen in iPA. Fibrinogen arrays were prepared using fibrinogen 
solutions with and without Cy3 labelled BSA. Blood from three healthy donors was 
incubated for 30 minutes on these arrays and the percentage of occupied fibrinogen 
dots was calculated. The addition of Cy3 labelled BSA to the fibrinogen solution had 
no effect on platelet adhesion 
 
3.2.2.5 Storage of the fibrinogen array 
The fibrinogen arrays can be stored in PBS at 4°C. It was investigated for how long 
the array could be stored. Fibrinogen solution at 200 µg/ml was printed as previously 
described (see Materials and Methods) and the array was stored for 1, 2, 3 weeks in 
PBS at 4°C. It was found that platelets were captured in all samples therefore the 
array could be stored for up to three weeks in these conditions.  
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Figure 3.2.2.5: Platelets adhering to the iPA surface that has been stored over 
time. i) iPA surface stored one week in PBS at 4ºC. ii) iPA surface stored two weeks 
in PBS at 4ºC. iii) iPA surface stored three weeks in PBS at 4ºC. Platelets were 
labelled with anti-CD41 and alexa 488. 
 
3.2.3 Platelet incubation time in iPA 
To determine the optimal incubation time for maximal adhesion to the fibrinogen 
array, platelet adhesion was measured over a range of time points (5 – 40 minutes). 
Platelets adhere to the fibrinogen array in a time dependent manner, with increasing 
platelet adhesion from 5 to 40 minutes (Figure 3.2.3). Results revealed that the 
percentage of occupied dots was 9.6 % and 9.2 % in donor 1 and 2 respectively at 5 
minutes and 70.5 % and 75.5 % in donor 1 and 2 at 40 minutes. The increase in 
platelet adhesion was linear up to 40 minutes. For the development of a platelet 
function assay we need short incubation times. Most available POC devices require 
less than 30 minutes for incubation. We have chosen 30 minutes for iPA since this 
will give us a broad measuring range (67.6 % adhesion median).  
59 
 
0 10 20 30 40 50
0
20
40
60
80
100
Donor 1
Donor 2
Time (min)
%
 O
c
c
u
p
ie
d
 d
o
ts
 
Figure 3.2.3: Platelet adhesion to fibrinogen microdots increases over time 
(median ± range). The percentage of occupied dots was measured after 5, 10, 15, 
20, 30, 40 minutes in 2 healthy donors in duplicate. Platelet adhesion increased in a 
linear fashion from 5 to 40 minutes. 
 
3.2.4 Platelet labelling 
It has been shown before (Basabe-Desmonts et al) that platelets can be observed in 
the novel adhesion assay using an anti-CD41 antibody (integrin alpha IIb chain) and 
a secondary antibody such as alexa 488. It was then examined whether platelets 
could be detected in this assay with a single step dye namely 3,3′-
dihexyloxacarbocyanin iodide (DiOC6). DiOC6 is a lipid dye which is internalised in 
the cell by simple diffusion and it localises in the endoplasmic reticulum and 
mitochondria of platelets. 1µM DiOC6 (Invitrogen, USA) fluorescence dye was 
added to the whole blood before incubation on the fibrinogen array. No additional 
wash steps were added. It was found that adding DiOC6 to the whole blood in the 
novel adhesion assay enables detection of platelets. On the other hand when DiOC6 
was used the background noise of the picture was so high that it was difficult to 
calculate how many platelets adhere to the fibrinogen array (Fig. 3.2.4).     
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                          Fibrinogen/Cy3-BSA       Platelets                                 
    
    
Figure 3.2.4: Platelet labelling using anti-CD41 and alexa 488 has more quality 
than DiOC6 in iPA. Fibrinogen mixed with Cy3-BSA is shown in red and platelets 
binding to iPA assay are shown in green. Platelets were labelled either with CD41-
alexa 488 (top right corner) or with DiOC6 (down right corner).  
 
 
3.2.5 Amount of printed dots needed for accurate measurement 
The microdot array used in the novel adhesion assay has over ten thousand 6µm 
fibrinogen dots. In this section, the number of dots needed for accurate measurement 
of platelet adhesion with less significant variation was determined. Blood from three 
healthy donors was collected and incubated with three different arrays of fibrinogen 
as previously described. Platelets were labelled and pictures were taken. The 
percentage of platelets binding to fibrinogen is automatically calculated using a 
computer program (see material and methods) which is based on a digital read out of 
the number of printed fibrinogen dots and the number of platelets binding to those 
dots. The mean adhesion for the three healthy donors (A, B and C) was calculated 
counting 1000, 1500 and 3000 dots. The assay reproducibility was calculated using 
the standard deviation of the platelet adhesion in the three different arrays of 
fibrinogen. As shown in Table 3.2.5 the assay variation in adhesion was an average 
3.7 SD when 1000 dots were counted, 3.8 SD for 1500 dots and 5.8 SD for 3000 
CD-41 + 
Alexa 488 
DiOC6 
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dots. Therefore it was decided that in the novel assay 1000 dots would be counted to 
measure platelet adhesion. 
Table 3.2.5: Number of dots needed for accurate measurement of platelet 
adhesion by iPA. Platelet adhesion in three healthy donors (A, B and C) was 
calculated by counting 1000, 1500 or 3000 dots. Assay variation was calculated 
using the SD of the triplicates. Measuring platelet adhesion using 1000 dots result in 
a small (3.7) variation. 
 
Number of 
dots 
counted 
 
1000 
 
1500 
 
3000 
Donor A B C A B C A B C 
Mean 91.4 61.9 65.9 90 63 65 85.9 63.7 71.6 
SD 1.2 2.5 7.4 2.4 2.5 6.4 8.4 2.2 6.9 
Average 
SD 
3.7 3.8 5.8 
 
The assay reproducibility which was calculated using triplicates and represented as 
SD, increased when higher numbers of dots were counted. This is quite unusual and 
should be further studied. A possible explanation is that the platelet adhesion varies 
across the array so for example the inner part of the array has lower adhesion than 
the outer areas. So when many different areas are counted there is a slight increase in 
variation. 
 
3.2.6 Reference adhesion range in healthy donors 
To establish the normal reference range for platelet adhesion in our assay, blood was 
collected from 50 healthy donors. Percentage of occupied dots was calculated 
following the methods previously described. Following analysis, the normal 
adhesion range percentage was found to be 81% [63.2, 91.5] median [inter-quartile 
range (IQR)] (Fig. 3.2.6). 
 
62 
 
40 45 50 55 60 65 70 75 80 85 90 95 100
0
2
4
6
8
% Occupied dots
N
o
. 
o
f 
In
d
iv
id
u
a
ls
 
Figure 3.2.6: Histogram showing the distribution of percentage of occupied dots 
in a population of healthy donors (n = 50). Using our assay, platelet adhesion was 
measured in a cohort of 50 healthy donors. This histogram shows the distribution of 
platelet adhesion values in this cohort. 
 
3.2.7 Retrospective analysis of platelet adhesion in the healthy donors. Effect of 
gender, platelet count and platelet integrin αIIbβ3 levels on iPA 
After establishing the normal reference range for platelet adhesion in our assay, we 
investigated the effect of variables such as gender, platelet count and αIIbβ3 receptor 
count on platelet adhesion. Our healthy population (n = 50) consisted of 27 females 
and 23 males volunteers. When the population was split into two groups based on 
gender, platelet adhesion in men was 86.6% [63.8, 94.8] and in women 78.5% [61.5, 
86.4], median [IQR] (Fig.3.2.7.1). The difference in percentage of adhesion in males 
was compared to females. Data was not significantly different according to Mann-
Whitney Test. These results confirm previously published data from other groups 
showing no differences in platelet adhesion to fibrinogen between men and women 
[113].  
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Figure 3.2.7.1: Gender has no effect on platelet adhesion in iPA. The cohort of 
healthy donors (n = 50) was split in to two groups based on gender. There was no 
significant difference in platelet adhesion between males (n = 23) and females (n = 
27). 
 
Platelet count from 42 healthy donors was recorded. Five donors were discarded 
because they have platelet counts under 150 x 10
6
 platelets/ml while platelet counts 
from 37 donors were within the normal range of 150 – 400 x 106 platelets/ml. 
According to Spearman correlation there was no correlation between platelet count 
and platelet adhesion (Spearman correlation coefficient; 
 r = 0.11, p=0.5), indicating that platelet count has no effect on platelet adhesion in 
iPA (Fig. 3.2.7.2). 
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Figure 3.2.7.2: Platelet count has no effect on platelet adhesion to fibrinogen in 
iPA. There was no correlation between platelet count and platelet adhesion (r = 0.11, 
p=0.5), indicating that platelet count has no effect on platelet adhesion in iPA. 
 
Integrin αIIbβ3 mediates platelet adhesion to fibrinogen. There is significant inter-
individual variation in platelet αIIbβ3 levels. To assess if αIIbβ3 levels affect platelet 
adhesion, we assessed platelet adhesion and β3 levels in parallel in 11 healthy 
donors. There was no correlation between β3 receptor expression and platelet 
adhesion in this sample (r = -0.1) (Fig. 3.2.7.3). The proportion of confidence 
interval was 0.95 meaning that the probability that there is no correlation in the 
population is 95%. 
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Figure 3.2.7.3: β3 levels have no effect on platelet adhesion in iPA. To assess if 
αIIbβ3 levels affect platelet adhesion, we assessed platelet adhesion and β3 levels in 
parallel in 11 healthy donors. There was no correlation between β3 levels and 
platelet adhesion in our assay (r = -0.1) indicating that inter individual variation in 
αIIbβ3 levels do not influence platelet adhesion in iPA. 
 
3.2.8 Platelet adhesion in a control group with over 55 years of age 
In order to investigate if platelet adhesion was affected by the donor’s age, seven 
healthy donors over 55 years old were recruited. The platelet adhesion to fibrinogen 
microdots in the control group was calculated and compared to the reference 
adhesion range. All blood was treated to the same conditions. According to Mann 
Whitney Test, platelet adhesion was not significantly different in the over 55 years 
age group, 73.5% [55.8, 81.8] median [IQR] when compared to the reference 
adhesion range 81% [63.2, 91.5] median [IQR], p=0.19. (Fig. 3.2.8). Power 
calculation relies on making certain assumptions, which, in the case of a de novo 
assay, may be untenable. Therefore I do not present power calculations and predicate 
non-significant findings with the possibility of low statistical power. 
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Figure 3.2.8.: Age has not effect on platelet adhesion to fibrinogen microdots in 
iPA. Platelet adhesion was measured in seven healthy donors over 55 years and 
compared to the reference range (n=50). Platelet adhesion appeared to be not 
significantly different in both groups. 
 
3.2.9 In vitro effect of the αIIbβ3 antagonist abciximab on iPA 
These experiments were elaborated in conjunction with Prof. Lourdes Basabe-
Desmonts and Dr. Sofia Ramstrom who were post-doctoral researchers at my 
research group. 
Our assay is based on αIIbβ3 mediated platelet adhesion to fibrinogen. To prove the 
specificity and accuracy of iPA in measuring this interaction, we assessed platelet 
adhesion to fibrinogen dots in the presence of an αIIbβ3 antagonist (abciximab, more 
commonly known as Reopro). This approach would also allow us to assess whether 
the novel assay could be used to monitor the efficacy of αIIbβ3 receptor antagonists. 
The ability of iPA to measure αIIbβ3 receptor antagonists was compared with a well 
established technique namely PAC-1 binding by flow cytometry. PAC-1 is a 
monoclonal antibody raised against an activated αIIbβ3 and is a quantitative marker 
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of platelet integrin activation. PAC-1 binding measured by flow cytometry can 
measure the level of inhibition of αIIbβ3-fibrinogen binding by αIIbβ3 receptor 
antagonism. However, it is quite complex and can only be performed by specialised 
personnel. 
To study the in-vitro effect of αIIbβ3 inhibition, whole blood samples from healthy 
donors were incubated with varying concentrations of abciximab (0.5, 1, 1.5, 2, 2.5, 
5, 20 µg/mL). Maximum abciximab concentration has been estimated to be 5 µg/mL 
and the maximum effect 84 % inhibition of aggregation [114]. Platelet adhesion was 
measured using our novel assay and compared with TRAP induced PAC-1 binding, 
measured by flow cytometry. Increasing concentration of abciximab caused a dose 
dependent decrease in platelet adhesion in our assay and in PAC-1 binding 
(Fig.3.2.10). The effect of different concentrations of abciximab on platelet adhesion 
and PAC-1 binding was comparable. 2.5 µg/mL of abciximab caused an 82 ± 17% 
decrease in PAC-1 binding and completely inhibited platelet adhesion to 6 μm dots 
(Figure 3.2.10 C). Hence, our novel assay displays comparable sensitivity to flow 
cytometry when measuring αIIbβ3 inhibition in vitro. These results also show the 
specificity of our assay for the measurement of αIIbβ3 mediated platelet adhesion to 
fibrinogen. 
 
3.2.10 In vivo effect of abciximab on iPA 
Having established that iPA could detect the effect of αIIbβ3 inhibition in vitro, we 
next assessed whether we could detect the effect of αIIbβ3 inhibition ex vivo from 
abciximab treated patients undergoing percutaneous coronary intervention (PCI). 
Platelet adhesion was measured in patients before and after abciximab administration 
(Figure 3.2.10 D and E). Percentage of platelet adhesion was 48 ± 7 % (n = 3) prior 
to treatment and 2 % (n = 3) following treatment, indicating effective antagonism of 
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αIIbβ3. These results show that our assay is also capable of detecting the effect of 
αIIbβ3 inhibition ex vivo. Blood samples from two of the three patients were 
collected again 24 hours following PCI. In these 2 patients, platelet adhesion was 7 ± 
3%, indicating only partial recovery of normal platelet function 24 hours after 
administration of abciximab.  
  
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.10: Platelet adhesion assay accurately detects the effect of αIIbβ3 
inhibition (abciximab). A) Representative fluorescence images of glass substrates 
containing fibrinogen dot arrays (left) and fluorescently labelled adherent platelets 
(centre). The substrates were incubated for 30 min with whole blood containing 
increasing concentrations of abciximab. On the right, the software calculation of the 
percentage of occupied dots is showed. B) Plot of the abciximab effect measured by 
the novel assay. Error bars represent standard deviation of the duplicates. (C) 
Comparative results of abciximab effect on the novel assay and flow cytometry in 
five healthy donors. For flow cytometry experiments, whole blood was activated 
with TRAP and fibrinogen receptor activation was measured by PAC-1 binding. D) 
Abciximab effect in vivo in three coronary artery disease patients measured by the 
novel assay over time. E) Representative images of abciximab effect over time. 
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3.3 Conclusion 
The optimisation of iPA for accurate measurement of platelet adhesion is described 
in this chapter. Interestingly this assay is far superior at capturing platelets from 
whole blood than from PRP. Since the samples in this assay simulate conditions of a 
low flow, a possible explanation of how platelets from whole blood are more 
efficient at binding fibrinogen could be that the red blood cells (RBC) move to the 
centre of the flow and leave platelets and plasma to the bottom of the sample 
improving binding efficiency, a phenomenon explained by the Fahraeus–Lindqvist 
effect in vivo (Fahraeus & Lindqvist 1931) where under shear, RBCs migrate toward 
the centre of the vessels, thus leaving a near-wall cell-depleted layer where the 
platelets tend to concentrate. Another possible explanation is that in PRP samples 
platelets aggregate and do not bind the small 6µm dots which will hold only 1-3 
platelets as shown by Basabe-Desmonts at al. This aggregation in PRP samples 
could be due to higher platelets count or the ecto-ADPase activity in whole blood 
[115]. Platelets remain highly unresponsive in circulation due to the presence ecto-
ADPase activity on the surface of endothelial cells [116] and other whole blood 
components including red blood cells. Thus platelet responsiveness to any platelet 
activating factors (such as ADP) secreted during the PRP preparation or during the 
low flow assay itself by fibrinogen binding and subsequent platelet activation during 
the conditions of iPA would be largely reduced. However, this aggregation induced 
decrease in adhesion (shown in PRP) is essential for a successful measurement of 
platelet antagonism by the iPA assay and this effect is going to be discussed in later 
chapters.  
Another parameter investigated was the height of the fibrinogen dots. It was found 
that on average, the microdots are ~ 11nm in height. Importantly, this height shows 
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that the fibrinogen orientation on the glass slide is horizontal (side-on) [117] which 
is more efficient at inducing fibrinogen unfolding and platelet binding [35].  
This chapter also reveals the normal reference range for adhesion in our assay. The 
minimum number of reference values recommended to establish a normal reference 
range with a reference interval of 97.5% is n = 39 [118]. Hence, 50 healthy donors 
were recruited to calculate the normal reference range for platelet adhesion in our 
assay. The normal adhesion range was found to be 81% [41.2, 99.1] median [inter-
quartile range (IQR)].  
To conclude, it has been shown that iPA can detect αIIbβ3 inhibitors in vitro and ex 
vivo with sensitivity similar to flow cytometry and that whole blood is essential for 
the assay. Moreover the possible reasons behind this necessity have been highlighted 
and discussed.  
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Chapter 4 
Detection of anti-platelet drug effects by iPA 
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4.1 Introduction 
Cardiovascular disease is the leading cause of morbidity and mortality worldwide. In 
2008 alone, 17.3 million deaths (representing 30% of all deaths) were attributable to 
the complications of cardiovascular disease. It is expected to remain the leading 
cause of death globally, with the number of deaths expected to reach 23.6 million 
annually by 2030 (WHO statistics, 2012).  
Platelets are the key cellular components of arterial thrombi with platelet adhesion 
under high shear conditions being central to atherothrombosis. In brief arterial 
thrombosis occurs when platelets initially adhere and then aggregate.  
 As such, anti-platelet agents are commonly used in the prevention of acute vascular 
events in cardiovascular disease patients. The most commonly used agents are 
aspirin (a COX-1 inhibitor) and P2Y12 receptor antagonists, both of which are often 
prescribed together as dual anti-platelet therapy. The benefit of these agents has been 
proven in a large number of randomised controlled trials (Eikelboom et al, 2012). 
Despite their proven benefit, acute cardiovascular events still occur in patients taking 
anti-platelet agents. This has been described as “high on treatment platelet reactivity” 
and has been linked with poorer outcomes in patients. It has been postulated that 
monitoring the effectiveness of anti-platelet drugs would be beneficial for the 
management of coronary artery disease. Platelet aggregation is the most common 
technique used for monitoring anti-platelet drugs.  
As previously mentioned, the aim of this thesis is to develop a platelet function assay 
that can reliably detect anti-platelet therapy. As shown in chapter 3, the novel assay 
based on platelet adhesion to 6 μm fibrinogen dots is reliably able to detect the effect 
of αIIbβ3 inhibitors in vitro and ex vivo (Fig.3.2.10). How this assay (iPA) can also 
be used to reliably monitor the effect of aspirin and P2Y12 inhibitors will be 
described in this chapter. 
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4.2 Results 
4.2.1 Aspirin and P2Y12 inhibitors have no direct effect on iPA 
The most commonly used anti-platelet agents are aspirin and P2Y12 receptor 
antagonists. The P2Y12 receptor antagonist cangrelor does not require to be 
metabolised to become active. For this reason it was chosen to investigate P2Y12 
inhibition in this assay in vitro. Cangrelor is used in patients as a bolus at 30 µg/Kg, 
thus it could be found in plasma at a concentration of approximately 0.36 mg/L 
(0.5µM) [119]. Aspirin administration varies among cardiovascular patients from 
between 30 to 500 mg/day [120]. The final plasma concentration after aspirin intake 
depends on the dose and the type of aspirin taken (coated or buffered) with maximal 
concentrations at 8 µg/ml in presystemic circulation (40 µM) [121]. In this thesis we 
have used cangrelor and aspirin both at a concentration of 10 µM which is 
commonly used in research [122, 123]. To examine the effect of both, aspirin and 
cangrelor on platelet adhesion to fibrinogen by iPA blood samples from four healthy 
donors were incubated with 10 µM of aspirin and/or 10 µM cangrelor for 30 minutes 
at 37ºC. Platelet adhesion was measured as previously described (material and 
methods). Aspirin and/or cangrelor did not affect platelet adhesion to 6 μm 
fibrinogen dots in the assay. As shown in figure 4.2.1 the percentage of platelet 
occupied dots was 79 ± 8 % with aspirin treated blood, 89 ± 6 % with cangrelor 
treated blood, 84 ± 6 % with aspirin + cangrelor treated blood, and 72 ± 9 % for 
untreated blood (buffer, n = 4). 
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Figure 4.2.1: Aspirin and/or cangrelor do not affect platelet adhesion to 
fibrinogen microdots. Blood samples from four healthy donors were incubated with 
10 µM of aspirin and/or 10 µM cangrelor for 30 minutes at 37ºC, then platelet 
adhesion was measured. There was no difference in platelet adhesion to 6 μm 
fibrinogen with untreated (buffer), aspirin, cangrelor, or aspirin + cangrelor treated 
blood.  
 
4.2.2. Detection of P2Y12 inhibition using iPA 
To make possible the detection of P2Y12 inhibition in our assay we use the agonist 
ADP. Blood from three healthy donors was incubated with increasing concentrations 
of ADP (0.02, 0.2, 2, 20 µM) and platelet adhesion to fibrinogen was measured. 
Figure 4.2.2.1 B shows that ADP decreased platelet adhesion in a dose-dependent 
manner.  
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Figure 4.2.2.1: ADP decreases platelet adhesion to fibrinogen microdots. A: 
Representative images of the novel platelet adhesion assay in the buffer samples and 
ADP samples (20µM). Fibrinogen dots are labelled in red and platelets in green. B: 
Platelet adhesion to fibrinogen dots at increasing concentrations of ADP (0, 0.02, 
0.2, 2, 20 µM). Error bars represent standard deviation of three donors (n=3). 
 
Given that ADP decreases platelet adhesion in iPA, we investigated whether the 
ADP antagonist cangrelor will abrogate this effect. Blood samples from fourteen 
healthy donors were pre-incubated with cangrelor (10 μM) for 30 minutes and then 
with or without ADP (20µM). The samples were incubated on the fibrinogen 
microdot array and the adhesion was measured. As shown before, cangrelor alone 
did not affect platelet adhesion. The buffer samples had an adhesion percentage of 87 
± 7 % (mean ± SD) and cangrelor samples 90 ± 3 % (mean ± SD). In contrast the 
decrease in platelet adhesion associated with ADP (shown in figure 4.2.2.1) was 
completely abolished by 10 μM cangrelor. Samples incubated with 20 μM of ADP 
had an adhesion percentage of 17 ± 13 % (mean ± SD). The sample containing ADP 
(20 μM) and cangrelor (10 μM) had and adhesion percentage of 80 ± 13 % (mean ± 
A B 
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SD) (Fig. 4.2.2.2). These results reveal the ability of iPA to detect the effect of the 
P2Y12 receptor antagonist, cangrelor on platelet function.  
 
Figure 4.2.2.2: iPA can detect the effect of the P2Y12 inhibitor (Cangrelor) via 
addition of ADP. Platelet adhesion to fibrinogen dots in 14 healthy donors with no 
agonists (buffer), with 10 µM of cangrelor, with 20 µM ADP and with 20 µM ADP 
in the presence of 10 µM cangrelor. Error bars represent standard deviation of the 14 
donors (n=14). 
 
In parallel LTA experiments using 20 µM ADP with and without 10 µM cangrelor 
were performed with blood taken from these healthy donors. The percentage of 
aggregation when 20 µM ADP was used was in average 74 ± 19 % and 3 ± 2 % 
when combination of 20 µM ADP and 10 µM cangrelor were used. These last results 
showed that cangrelor was indeed working and able to inhibit aggregation using 
LTA. 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Buffer  Cangrelor (10µM) ADP (20µM) ADP + Cangrelor 
%
 O
cc
u
p
ie
d
 d
o
ts
 
78 
 
 
Figure 4.2.2.3: Platelet aggregation in 14 healthy donors using 20   ADP and 
ADP in combination with the P2Y12 inhibitor (Cangrelor). Error bars represent 
standard deviation of the 14 donors (n=14). 
 
4.2.3 Understanding the mechanism of drug detection by iPA 
We performed several experiments to understand why ADP induces a decrease of 
platelet adhesion in this assay. We hypothesise that platelets activation by ADP 
induce binding to plasma fibrinogen through the αIIbβ3 receptor which subsequently 
reduces the ability of platelets to bind to the fibrinogen array. To investigate this 
hypothesis we generated a microdot array with an anti-CD42b antibody. This 
antibody can bind to platelets through the GPIbα receptor even when platelet integrin 
αIIbβ3 is bound by plasma fibrinogen. Therefore, if our hypothesis is true, the 
platelets should bind to anti-CD42b even when activated by the agonist ADP. 
Interestingly however, results using blood from three healthy donors revealed that 20 
µM ADP reduced the percentage of platelet adhesion (1 ± 1 %, mean ± SD, Fig. 
4.2.3.1) in a manner similar to the reduction of platelets binding to the fibrinogen 
array. The percentage of platelet adhesion to the anti-CD42b array using a buffer 
control revealed a percentage of adhesion (49 ± 7 % (mean ± SD). Again, in the 
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CD42b surface array, cangrelor was able to abolish the reduction in platelet adhesion 
caused by ADP.  
We conclude that the hypothesis of the plasma fibrinogen - αIIbβ3 occupancy 
induced by ADP activation of platelets is not the reason for the reduction of platelet 
binding to the fibrinogen array. Although the fibrinogen - αIIbβ3 interaction possibly 
plays a role in iPA’s ability to measure the effect anti-platelet drugs. 
Interestingly, the anti-CD42b array also shows us that, if using the conditions 
described for iPA then other platelet surface receptors can be targeted to detect the 
effect of anti-platelet therapy.     
 
 
Figure 4.2.3.1: Platelet binding to an array of anti-CD42b with/without ADP 
and cangrelor. ADP decreased platelet adhesion to the anti-CD42b array thus 
showing that the decrease in adhesion induced by ADP is not due to fibrinogen 
occupancy, and therefore blockade of αIIbβ3. Cangrelor inhibited the effect of ADP 
in iPA. Mean platelet adhesion ± SD, n=3.  
 
Given that ADP also decreases adhesion to an array of anti-CD42b microdots we 
conclude that the decrease in platelet adhesion induced by ADP is not due to the 
binding of plasma fibrinogen to αIIbβ3.  
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Therefore we formulated a second hypothesis which states that in iPA ADP induces 
platelet aggregation and reduction of platelet count (single platelets) thus decreasing 
the availability of single platelets to adhere to the protein array. To investigate this 
hypothesis we measured the platelet count with and without cangrelor and/or ADP 
using a cell counter (Sysmex haematology analyser). In addition we measured 
platelet counts pre- and post- iPA. Blood samples from three healthy donors were 
collected and incubated in the presence or absence of 10 µM cangrelor in 
combination with or without 20 µM ADP. The average platelet count for the three 
healthy donors before incubation on the fibrinogen surface was 200 x 10
3
/µl ± 45 
(mean ± SD, Fig. 4.2.3.2). After incubation on fibrinogen for 30 minutes, platelet 
counts dropped to 189 x 10
3
/µl ± 33 (mean ± SD). In the presence of 10 µM 
cangrelor, platelet counts were marginally higher in comparison to the buffer control. 
When 20 µM of ADP was added the platelet count dramatically dropped to 55 x 
10
3
/µl ± 38 (mean ± SD). After 30 minutes incubation on the iPA array the platelet 
count was measured again and the decrease was still significantly low (107 x 10
3
/µl 
± 43 platelets (mean ± SD)). In the samples containing ADP and cangrelor (20µM, 
10 µM respectively) there was no significant drop in adhesion (before incubation 
with fibrinogen (207 x 10
3
/µl ± 34) and after incubation with fibrinogen (196 x 
10
3
/µl ± 36). We conclude that ADP induced a decrease in platelet adhesion which 
was related to a drop in platelet count which was then abrogated by 10 µM 
cangrelor. 
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Figure 4.2.3.2: ADP (20µM) decreases platelet count (measured by the cell 
counter Sysmex) before and after incubation on fibrinogen surface and 10µM 
cangrelor completely abolished this effect. Platelet count was measured in samples 
used for iPA. Buffer control shows the platelet count with no agonist or drug 
treatment, measured before and after iPA. Cangrelor does not significantly affect 
platelet count. 20 µM ADP dramatically reduces platelet count. Cangrelor reverses 
this reduction in platelet count. Error bars represent standard deviation of three 
donors (n=3). 
 
The decrease in adhesion induced by ADP reflects a drop in platelet count but we do 
not know how ADP affects other blood cell levels. We have shown before that whole 
blood and not PRP is required in iPA for platelet adhesion (chapter 3, fig. 3.2.1). 
Therefore red blood cell (RBC) and white blood cell (WBC) levels could affect 
platelet binding to iPA. In order to investigate whether ADP causes a reduction in the 
cell count of other blood cells we repeated the experiment and included the 
measurement of red blood cell (RBC) and white blood cell (WBC) levels. 
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Table 4.2.3.3: ADP induces a decrease in the number of single platelets, 
measured by the cell counter Sysmex. 20 µM ADP induced a decrease in platelet 
count from an average of 142 x 10
3
/µl to 7.3 x 10
3
/µl platelets (mean ± SD). 10 µM 
cangrelor inhibited this effect in three healthy donors. However, the number of red 
blood cells (RBC) and white blood cells (WBC) were unaffected by ADP (n=3). 
Mean ± SD RBC10
6
/µl WBC10
3
/µl 
Platelet 
count10
3
/µl 
Adhesion % 
Buffer 3.5 ± 0.4 6.5 ± 1 142.3 ± 50 64.7 ± 19 
ADP 3.4 ± 0.5 6 ± 1 7.3 ± 6 10.4 ± 6 
ADP + Cangrelor 3.7 ± 0.2 7.3 ± 2 119.3 ± 66.5 44.2 ± 31.4 
 
To investigate the effect of platelet count reduction on iPA serial dilutions were 
preformed with the blood samples using HEPES buffer. Platelet counts were 
measured in parallel with platelet adhesion to fibrinogen. The dilutions chosen were 
(1:2, 1:2.5, 1:3.3, 1:5 and 1:10) and the final sample volume was 1000 µl. The 
diluted samples and a control (no dilution) were incubated on the fibrinogen 
microdot array as previously described. Platelet count was measured before and after 
blood incubation using a Sysmex device. We found that sample dilutions 
proportionally decreased both platelet count and platelet adhesion respectively (Fig. 
4.2.3.4). When a 1:2 dilution was used platelet count dropped 44 % from its 
undiluted values and the percentage of occupied dots dropped 40 %.  
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Figure 4.2.3.4: Serial dilutions of whole blood decreased platelet count and 
platelet adhesion to the fibrinogen array in three healthy donors. A) Platelet 
count with the indicated serial dilutions pre- and post incubation with iPA. Error bars 
represent standard deviation (n=3). B) Platelet adhesion with the indicated serial 
dilutions post incubation with iPA. Error bars represent standard deviation (n=3). 
 
In summary this data shows that the mechanism by which ADP induces a decrease in 
platelet adhesion to the iPA fibrinogen array is directly related to a drop in the 
platelet count caused by platelet aggregate formation. 
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4.2.4 Detection of aspirin effect using iPA 
Some of the work included in this section was completed in collaboration with Dr. 
Bincy Jose from the Biomedical Research institute (BDI) in Dublin City University 
(DCU) in Ireland. 
After showing that P2Y12 inhibition could be detected in this assay by using ADP, 
we next investigated if we could detect the effect of aspirin using AA. The AA 
concentration used was the 500 µg/ml since this is the concentration recommended 
for AA induced aggregation in LTA. Three healthy donors were recruited and LTA 
together with the novel adhesion assay on fibrinogen microdots were performed. The 
percentage of occupied dots in the buffer sample was 72 ± 17 % (mean ± SD, 
Fig.4.2.4.1.1) and aspirin alone (10µM) did not affect platelet adhesion to fibrinogen. 
AA was able to decrease the adhesion to 5 ± 1 % (mean ± SD) but in this case 10 
µM of aspirin (ASA) was not able to inhibit the decrease in adhesion induced by 
AA. Therefore iPA could not be used to detect aspirin effect when using 500 µg/ml 
of AA.  
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Figure 4.2.4.1.1: AA (500 µg/ml) decreased platelet adhesion to fibrinogen 
microdots in three healthy donors but 10µM aspirin did not inhibit this effect. 
Buffer control reveals normal platelet adhesion. 10 µM aspirin had no effect on 
adhesion. 500µg/ml AA significantly reduced platelet adhesion. Aspirin had no 
effect on AA induced decrease in platelet adhesion. Error bars represent standard 
deviation (n=3). 
 
LTA results showed that 500 µg/ml AA induced aggregation 82 ± 15 % (mean ± SD, 
Fig: 4.2.4.1.2) and 10 µM aspirin was able to completely inhibit this effect.  
 
 
Figure 4.2.4.1.2: A) Representative aggregation trace of a healthy donor 
showing maximum aggregation and slope using buffer (PBS), 500 µg/ml of 
arachidonic acid (AA) with or without aspirin (µM) and 20µM ADP. B) Platelet 
aggregation with AA (500 µg/ml) and with AA in combination with 10µM 
aspirin in three healthy donors. Error bars represent standard deviation (n=3). 
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Following these results, the concentration of AA was lowered to 50 µg/ml which is 
the concentration recommended for whole blood aggregation (WBA). In these 
experiments instead of LTA we performed whole blood aggregation.  
Whole blood aggregation was performed using Whole Blood Lumi-Ionized calcium 
aggregometer Model500CA/560CA (Chrono-Log Corporation, Havertown, USA). In 
brief, the aggregometer was turned on and allowed to warm up to 37°C. Blood 
samples were incubated with 10 µM aspirin for 30 minutes at 37°C. Then 500 µl of 
whole blood with or without aspirin was pipetted in a cuvette containing stir bar and 
450µl of saline (0.9% w/v Sodium Chloride from Sigma). The maximum and 
minimum impedance was set at each channel and the run was restarted. The sample 
ran for 1 minute and 50 µl of the agonist was added (50µg/ml of AA). The sample 
was allowed to run for 10 minutes and the maximum impedance and the slope were 
recorded. 
For these experiments eleven healthy donors were recruited and WBA and iPA were 
performed simultaneously. The whole blood aggregometer revealed an average of 
impedance of 24.5 ± 9 ohm (mean ± SD, Fig. 4.2.4.2) which was totally abrogated 
with 10 µM of aspirin. The mean adhesion using our assay was 81.5 ± 4 % (mean ± 
SD) in the buffer sample and 49.5 ± 7 % (mean ± SD) using 50 µg/ml of AA. 
Aspirin inhibited the effect of AA and the mean adhesion using 10 µM of aspirin in 
combination with AA was 68 ± 12 % (mean ± SD). 
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Figure 4.2.4.2: AA (50 µg/ml) enables detection of aspirin effect in iPA. A) 
Whole blood aggregation was measured using AA (50 µg/ml) with or without aspirin 
(10 µM), error bars represent standard deviation (n=11). B) Platelet adhesion using 
iPA. AA (50 µg/ml) enables detection of aspirin effect, error bars represent standard 
deviation (n=11). 
 
This data shows that the novel platelet adhesion assay was able to detect aspirin 
effect when using an agonist dose of 50 µg/ml. However the detection is less 
sensitive than in the case of P2Y12 inhibitors as the samples containing AA alone 
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when compared with AA in combination with aspirin did not differ to a great extent 
and error bars nearly overlap. 
Therefore we continued to optimise the assay and improve outcomes by modifying 
the experimental conditions. For these experiments with AA we improved the 
mixing of the agonist, thus making sure it was homogeneously spread through the 
sample. For this reason we stirred the samples after adding the agonist and before 
placing it on the rocking table. In order to keep all the samples under the same 
conditions, the stirring was applied in all samples (1200 rpm for 2 min). The 
percentage of occupied dots in the buffer sample was 60 ± 17 % (mean ± SD, Fig. 
4.2.4.3) in n=10. After addition of 50 µg/ml of AA at stirring conditions the 
percentage of occupied dots was 16 ± 13 % (mean ± SD) and 49 ± 13 % (mean ± 
SD) in the sample with AA and 10 µM aspirin. This data shows that iPA was able to 
detect aspirin effect by using 50 µg/ml of AA in a more accurate manner when the 
samples were stir at 1200 rpm (Figure 4.2.4.3).  
 
 
Figure 4.2.4.3: Stirring conditions pre-iPA enables more accurate detection of 
the effect of aspirin on platelet function when using AA at a concentration of 
50µg/ml. Buffer control reveals normal platelet adhesion. Arachidonic dramatically 
reduces platelet adhesion to the fibrinogen microarray and aspirin significantly 
reduces this effect. Error bars represent standard deviation (n=10). 
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4.2.5 Comparising iPA with other platelet function tests. Light transmission 
aggregometry and VerifyNow
® 
While not routinely performed clinically, P2Y12 receptor inhibition can be monitored 
by other platelet function tests, including LTA and the VerifyNow
® 
P2Y12 cartridge. 
To compare iPA with VerifyNow
®
 and LTA’s ability to detect P2Y12 inhibition, 
whole blood samples from a healthy donor was pre-treated with varying 
concentrations of the P2Y12 antagonist cangrelor (0, 0.005, 0.01, 0.05, 0.1, 0.5, 1 
µM), and assayed using the three tests in the presence of 20 µM ADP (Fig. 4.2.5). 
All three assays detected the effect of P2Y12 inhibition. iPA showed an inverse 
correlation with both LTA (r = -0.898, and the VerifyNow
®
P2Y12 cartridge (r = -
0.855, fig. 4.2.5). The inverse correlation is explained by the fact that ADP increases 
the percentage of aggregation in LTA and the VerifyNow
®
, but decreases platelet 
adhesion to fibrinogen in iPA.  
The results of the VerifyNow
® 
P2Y12 cartridge correlated with LTA (r=0.99). 
Moreover, iPA not only correlated well with both LTA and the VerifyNow
®
, it also 
showed a broader measuring range than both assays. Figure 4.2.5 shows that results 
from the novel assay changed with cangrelor at concentrations where LTA and 
VerifyNow
®
 were saturated. Neither LTA nor VerifyNow
® 
were able to detect 
differences between samples when cangrelor concentrations were higher than 0.1 
µM. In contrast, percentage of occupied dots in samples with 0.1, 0.5, and 1 µM 
cangrelor were 26 ± 3, 33 ± 0.5, and 43 ± 3 (% ± SD) respectively. Percentage of 
aggregation by LTA in samples with 0.1, 0.5, and 1 µM cangrelor were 35 ± 3, 33 ± 
3 and 24 ± 2 (% ± SD) and PRU by VerifyNow
®
 58 ± 14, 45 ± 4 and 31 ± 3 
respectively (Figure 4.2.5). This data correlates with previous reports showing that 
VerifyNow
® 
was not able to detect difference in platelet inhibition at high levels of 
P2Y12 blockage [81].   
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Figure 4.2.5: The ability of the novel platelet adhesion assay, iPA to detect 
P2Y12 inhibition correlates with both LTA (r=-0.898) and the VerifyNow
®
 P2Y12 
cartridge (r=-0.85) in vitro. The measurement of platelet inhibition by the three 
different techniques was compared using a combination of ADP 20 µM and 
increasing concentrations of cangrelor (0, 0.005, 0.01, 0.05, 0.1, 0.5, 1 µM). Error 
bars range of the duplicates.  
 
 
 
 
 
 
 
 
91 
 
4.3 Conclusion 
In this chapter it was shown that iPA can detect the effect of the anti-platelet drugs 
aspirin and the P2Y12 inhibitors. The mechanism of drug detection is based on the 
decrease in the number of single platelets capable of binding the fibrinogen array 
upon addition of an agonist. This decrease in platelet adhesion can be abrogated by 
the agonist-specific inhibitor, thus enabling detection of anti-platelet drug effect. For 
the detection of the aspirin effect AA was used as the agonist. It was found that at 
high concentration of AA (500µg/ml) which is commonly used in LTA aspirin effect 
cannot be detected by iPA. This can be explained by the fact that other blood cells 
such as monocytes can produce thromboxane [64] and therefore provide an 
additional positive feedback loop to the pathway to which aspirin inhibits. These 
results highlight the importance of using whole blood versus PRP to measure platelet 
function. However, lower doses of AA (50µg/ml) relevant to platelet aggregation 
measured by whole blood aggregometry proved to be effective for detecting aspirin’s 
anti-platelet effect by iPA. Furthermore for the detection of the aspirin effect the 
blood samples were stirred together with AA which improved the detection of the 
the aspirin effect. The reason why this stirring improved the assay detection is not 
fully understood. One hypothesis is that AA requires to be well mixed with the blood 
sample to be more efficient. Another hypothesis is that the shear created by stirring 
is needed in the process of aggregation with AA. 
It was also shown in this chapter how the platelet inhibitors aspirin and cangrelor do 
not affect platelet adhesion to our assay. This data validates previous data showing 
that aspirin do not affect platelet adhesion to fibrinogen under shear [82]. 
The capability of the assay in detecting P2Y12 inhibition was compared with light 
transmission aggregometry (LTA) and with the VerifyNow
®
 (Figure 4.2.5). There 
was a high correlation between the three assays. Most importantly, iPA was more 
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sensitive at detecting P2Y12 inhibition with high concentrations of cangrelor, while 
LTA and VerifyNow
® 
reached a plateau at concentrations above 0.1µM cangrelor. 
This can be explain by the fact that the novel assay uses an array of 6 µm protein 
dots ensuring that single platelets are assayed in a manner that enables direct 
assessment of a fraction of platelets without complication by multi-platelet 
phenomena.  
In summary, we have developed an improved whole blood assay that reliably and 
specifically detects anti-platelet drug effects by measuring platelet adhesion and 
aggregation (indirectly) and which has the potential to improve and personalize anti-
platelet therapy. 
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Chapter 5 
Detection of anti-platelet drug effects and bleeding risk in 
patients by iPA 
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5.1 Introduction;  
5.1.1 Coronary artery disease 
Coronary artery disease or coronary heart disease is the leading cause of mortality in 
the developed countries [4]. Coronary artery disease originates from atherosclerosis 
of the coronary arteries, which is an accumulation of abnormal deposit of 
cholesterol, fat and other substances in the coronary arteries. Coronary artery disease 
is divided into chronic coronary artery disease and acute coronary artery disease 
(ACD). As mentioned before platelet activation is a major complication in patients 
with acute coronary syndrome and can cause adverse cardiovascular events due to 
platelet mediated thrombosis [57, 58]. The medication prescribed for platelet 
inhibition in coronary artery disease patients comprised aspirin and thienopyridines 
which have been described previously in this thesis. Aspirin inhibits thromboxane 
production thus inhibiting platelet activation. It has been also postulated that aspirin 
increases production of nitric oxide (NO) and decreases inflammation which are 
factors associated with platelet inhibition [124]. It has been shown that aspirin 
decreases acute myocardial infarction by approximately 33 % [125]. Aspirin non 
response varies between 5-60 % in patients taking this drug and it is more common 
in elderly, females and patients with type 2 diabetes which have higher platelet 
turnover. On the other hand clopidogrel is a pro-drug that has to be metabolised in 
order to become active therefore the response to this drug is highly variable. In this 
chapter coronary artery disease patients have been recruited and their response to 
anti-platelet drugs has been investigated using iPA. 
Additionally there are other non anti-platelet drugs which affect platelet function, for 
instance it has been shown that the anti-psychotic drug clozapine is a calmodulin 
inhibitor [126]. Calmodulin has an important role in platelet function such as 
activation of calcium-modulated enzymes [127]. Clozapine has been shown to 
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decrease ADP induced aggregation in vitro by LTA [128]  but these results have not 
yet been reproduced in vivo. Therefore we have also investigated the effect of 
clozapine in schizophrenic patients using iPA. 
 
5.1.2 Platelet related bleeding disorders  
Anti-platelet medication has been shown to be beneficial for coronary artery disease 
patients however it increases the risk of bleeding in these patients. Aspirin has the 
lowest bleeding related risk with a rate of 3.6 % and GPIIbIIIa inhibitors the highest 
with 46 % [129].  
Patients taking anti-platelet drugs and who suffer from uremia have a higher risk of 
bleeding. Uremia is a generic term to describe a series of symptoms associated with 
fluid, electrolyte, and hormone imbalance and metabolic abnormalities which 
develop in parallel with deterioration of renal function. In particular the nitrogenous 
waste products (urea), which are normally excreted through the urine, are retained in 
the blood in uremic patients. Dialysis helps to eliminate toxins from the body and 
decrease uremic symptoms. There are two main types of dialysis; haemodialysis and 
peritoneal dialysis. In haemodialysis, the patient’s blood is drawn, filtered ex vivo 
and replaced. In peritoneal dialysis a fluid is placed into the patient’s abdominal 
cavity which acts as a filter. Uremic patients have a tendency to bleed [130], a 
complication not related to the patients coagulation system [131]. Moreover, there is 
an association between platelets dysfunction and uremia. We wonder, would our iPA 
assay detect a platelet abnormality in renal failure patients. 
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5.2 Results 
5.2.1 Coronary artery disease patients 
5.2.1.1 Platelet adhesion in coronary artery disease patients and control group 
measured by iPA 
Blood from an age-matched control group (healthy donors over 55 years) and 
coronary artery disease patients (CAD) was collected and basal platelet adhesion was 
measured by iPA. CAD patients were divided into two cohorts namely CAD patients 
on aspirin alone or CAD patients on dual anti-platelet medication (aspirin and 
thienopyridines). There was no significant difference observed between the control 
group and the CAD cohorts as measured by Kruskal Wallis test. 
Platelet adhesion from the control group was 73.5% [55.8, 81.8] median [IQR] (n=7) 
whilst platelet adhesion from the CAD patients on dual anti platelet therapy and 
CAD patients on aspirin alone was 71.8% [61.7, 78.2] median [IQR] (n=23) and 
74.4% [65.9, 80.7] median [IQR] (n=12) respectively.  
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Figure 5.2.1.1: iPA analysis of platelet adhesion to fibrinogen from CAD 
patients versus healthy controls. Platelet adhesion from the age-matched control 
group (n=7) was compared with platelet adhesion from patients with acute coronary 
syndrome who were on single (n=12) or dual (n=23) anti-platelet medication. Data 
represents percentage of platelet adhesion to fibrinogen micro dots. Results revealed 
no significant difference in adhesion between all three groups according to Kruskal 
Wallis test. 
 
5.2.1.2 Using iPA to detect P2Y12 inhibition in CAD patients 
As shown in chapter 4, iPA enables detection of P2Y12 inhibition in vitro by adding 
ADP to the blood sample. We investigated if iPA could detect P2Y12 inhibition in 
vivo. Twenty three coronary artery disease patients on dual anti-platelet medication 
(aspirin and P2Y12 inhibitors) were recruited and their platelet aggregation was 
measured after clopidogrel intake. Patients were then divided into responders and 
non-responders to clopidogrel according to LTA. Aggregations over 64 % are typical 
of non responders to clopidogrel when 20µM ADP is used [83]. However this cut-off 
point may not be optimal and ideally non-responders are classified by a reduction of 
<10 % in their aggregation after clopidogrel administration [132]. The reduction in 
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the aggregation response is only possible to calculate when patient blood is collected 
also before taking clopidogrel and this is difficult to accomplish. Therefore blood 
was only collected after clopidogrel intake (at least 3 months after) and 64 % 
aggregation (20µM ADP) was used as the cut-off point for LTA to define response 
to clopidogrel. 
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Figure 5.2.1.2: Identification of coronary artery disease patients who are 
responders to clopidogrel. Blood from 23 coronary artery disease patients on 
aspirin and P2Y12 inhibitor was taken and platelet aggregation was measured (20µM 
ADP). The cohort was divided into responders and non-responders by a cut-off point 
of 64 % aggregation. Patients with aggregations higher that 64 % are considered non 
responders to clopidogrel. 
 
Then platelet adhesion was measured with the addition of ADP (adhesion
ADP
) and 
without the addition of ADP (adhesion
buffer
). To enable comparison of the patients 
response to ADP, platelet adhesion was normalised via this simple equation 
(adhesion
ADP
*100/adhesion
buffer
). In figure 5.2.1.3 we show how iPA can detect the 
effect of P2Y12 inhibitors in coronary artery disease patients who are responders to 
this drug (aggregation lower than 64%). Normalised platelet adhesion with 20µM 
ADP (grey bars) is 13.6% [7.5, 21.5] median [IQR] (n=7) in the control group and 
13.3% [8.8, 17] median [IQR] (n = 14) in CAD patients on aspirin while CAD 
Non-responders 
Responders 
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patients on dual anti-platelet medication who are responders to clopidogrel have an 
adhesion range of 31.5% [25.4, 47] median [IQR] (n = 12). One-way ANOVA 
analysis illustrates that platelet adhesion from patients taking P2Y12 inhibitors is 
significantly higher than the control group or the patients on aspirin alone 
(p≤0.0001) when ADP was added (adhesionADP). Platelet adhesion when ADP was 
added (adhesion
ADP
) in patients taking aspirin alone is not significantly different than 
the control group therefore the assay is specific for detecting P2Y12 inhibition. This 
data reveals to us that the novel assay, iPA can detect P2Y12 inhibition amongst CAD 
patients on dual antiplatelet therapy.  
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Figure 5.2.1.3: The novel platelet adhesion assay specifically detects the effect of 
P2Y12 inhibition in patients. Blood from healthy donors (n=7), patients on aspirin 
(n=14) and patients on aspirin and P2Y12 inhibitor (n=12) was taken and platelet 
adhesion was calculated (white bars, median [IQR], n=33). When ADP was added to 
the sample (grey bars) platelet adhesion dropped in healthy donors and patients on 
aspirin while in patients on aspirin and P2Y12 inhibitors the decrease was less 
significant. According to Kruskal Wallis Test and Dunn’s multiple comparison post 
test, platelet adhesion in patients on aspirin and P2Y12 inhibitors was significantly 
different then platelet adhesion in healthy donors and patients on aspirin only 
(p≤0.0001). There was no significant difference in platelet adhesion from patients on 
aspirin and from the healthy controls when ADP was added. Therefore the assay is 
specific for detection of P2Y12 inhibition.  
 
In order to compare iPA and LTA, both results were plotted together (Fig. 5.2.1.4). 
Then a cut-off point for iPA was defined as 36 % occupied dots since this number 
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gave the best compromise for specificity and sensitivity to detect non-responders 
compared to LTA according to ROC analysis (area of 0.92). Based on the LTA cut-
off point, 11 patients in our cohort of 23 were considered non-responders to 
clopidogrel therapy. These same 11 patients were also identified as non-responders 
to clopidogrel therapy by iPA (Fig.5.2.1.4). Interestingly, however, we showed that 4 
patients were classified as responders by LTA but appeared as non-responders when 
measured by iPA. 
The iPA data related to CAD patients was non-parametric and therefore Spearman 
coefficient was calculated. There was a correlation of r=-0.73, p≤0.0002.  
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Figure 5.2.1.4: Comparison of LTA with iPA for detection of P2Y12 inhibition 
from acute coronary syndrome patients on dual anti-platelet therapy. 
Spearman correlation coefficient is r=-0.73 (p≤0.0002). Each point represents a 
single CAD patient. The x-axis represents the percentage of aggregation and y-axis 
the percentage of adhesion in response to 20µM ADP. The vertical line represents 
the cut-off point for LTA (64% aggregation) while the horizontal line is the cut-off 
point for iPA (36 % occupied dots). The inverse correlation indicates that the higher 
the aggregation the lower the adhesion and vice versa. 
 
LTA and VerifyNow
®
 P2Y12 are the most commonly used platelet function tests 
available. In order to compare these two assays ability to detect P2Y12 inhibition ten 
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coronary artery disease patients were recruited and their aggregation and Platelet 
Reactivity Units (PRU- VerifyNow
®
) were measured. The data was parametric and 
Pearson coefficient was 0.79 (p≤0.0001, Fig. 5.2.1.5) 
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Figure 5.2.1.5: Comparison of LTA and VerifyNow
®
 for detection of P2Y12 
inhibition in acute coronary syndrome patients. Pearson correlation coefficient 
is r=0.79 (p≤0.0001). Each point represents a single CAD patient’s response to 
20µM ADP. The x-axis represents the percentage of aggregation and the y-axis 
represents the PRU by VerifyNow
®
. The vertical line is the cut-off point to define 
non-response using LTA (64% aggregation) and the horizontal line is the cut-off 
point for VerifyNow
®
 (>230 PRU [133]). 
 
5.2.2 Effect of the calmodulin inhibitor clozapine on platelets measured by iPA 
The new generation anti-psychotic drug clozapine has been shown to decrease ADP 
induced aggregation in vitro. In order to assess whether clozapine decreases the ADP 
response in vivo a cohort of fifteen schizophrenic patients was recruited and analysed 
using iPA. Seven of these patients were taking first generation anti-psychotic drugs 
(zuclopenthixol, flupenthixol or risperdone) and eight were on the second generation 
anti-psychotic drug, clozapine. In parallel five healthy donors matched for age and 
gender were recruited. Firstly blood was collected and basal platelet adhesion (no 
ADP) was measured. Basal platelet adhesion in these patients was not significantly 
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different compared to controls according Kruskal Wallis test. Platelet adhesion was 
51% [37.4, 51.8] median [IQR] (n = 7) in the control group and 65.6% [54.3, 78.1] 
median [IQR] (n = 7) in patients on first generation anti-psychotic drugs and 58.7% 
[36.6, 77.4] median [IQR] (n = 8) in patients on clozapine (Fig. 5.2.2.1).  
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Figure 5.2.2.1: Platelet adhesion in controls (n=5) and schizophrenic patients on 
first generation anti-psychotic drugs (n=7) or clozapine (n=8) are not 
significantly different.  
 
Then we investigated whether clozapine decreases ADP response in vivo in iPA (Fig. 
5.2.2.2). Normalised platelet adhesion (adhesion
ADP
*100/adhesion
buffer
) (grey bars) is 
8.4% [6.8, 9] median [IQR], (n = 7) in the control group and 13.2% [7.6, 19.5] 
median [IQR] (n = 7) in schizophrenic patients on first generation anti-psychotic 
drugs while schizophrenic patients on clozapine have an adhesion of 33% [14.5, 
61.83] median [IQR] (n = 8). According to Kruskal-Wallis test platelet adhesion 
with ADP on patients taking clozapine is significantly higher than in patients on first 
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generation anti-psychotic drugs and in the control group (p≤0.01), thus the novel 
assay demonstrates a novel effect of clozapine. 
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Figure 5.2.2.2: iPA detects the effect of the calmodulin inhibitor clozapine in 
schizophrenic patients. Blood from age-matched healthy donors (n=7) and 
schizophrenic patients taking clozapine (n=8) or first generation anti-psychotic drugs 
(n=7) was taken and platelet adhesion was measured (white bars, median [IQR] 
n=22). When ADP was added to the samples (grey bars) platelet adhesion radically 
decreased in healthy controls and schizophrenic patients on first generation anti-
psychotic drugs while in patients taking clozapine the decrease was less significant 
according to one way Kruskal-Wallis test (p≤0.01). 
 
5.2.3 Platelet related bleeding measured by iPA 
In order to investigate bleeding risk using iPA a cohort of twenty-nine renal failure 
patients was recruited from which five were on peritoneal dialysis, twelve were on 
haemodialysis and an additional twelve were on haemodialysis and taking aspirin. In 
parallel six healthy donors were recruited as controls. Blood was collected and basal 
platelet adhesion was measured. Platelet adhesion in renal failure patients on 
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haemodialysis taking aspirin was significantly different than the controls according 
to Kruskal-Wallis test (p≤0.01). Platelet adhesion was 63.9% [60, 77.2] median 
[IQR] (n = 6) in the control group and 60% [57.1, 70.4] median [IQR] (n = 5) in 
patients on peritoneal dialysis whilst in patients on haemodialysis the platelet 
adhesion was 66.2% [47.2, 74.5] median [IQR] (n = 12) and 48% [37, 52.7] median 
[IQR] (n = 12) in patients on haemodialysis taking aspirin (Fig. 5.2.3).  
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Figure 5.2.3: Platelet adhesion in renal failure patients compared to healthy 
controls. Platelet adhesion in renal failure patients in peritoneal dialysis (n=5) and 
on haemodialysis (n=12) was not significantly different than controls (n=6) while 
platelet adhesion renal failure patients on haemodialysis taking aspirin (n=12) was 
significantly lower than controls according to one-way Kruskal-Wallis test (p≤0.01). 
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5.3 Conclusion 
This chapter focuses on the ability of the iPA assay to measure platelet function in 
vivo in several patient cohorts. Firstly we have shown that platelet adhesion is not 
significantly different between coronary artery disease patients on anti-platelet drugs 
and healthy donors. This correlates with the in vitro results in chapter 4, where we 
have shown that anti-platelet drugs have no direct effect in platelet adhesion to 
fibrinogen. 
Second and most important, we confirmed that iPA can be used to detect P2Y12 
inhibition in patients. Monitoring P2Y12 inhibition is possible when ADP is added to 
the blood sample. Platelets from patients taking P2Y12 inhibitors do not aggregate to 
ADP thus platelet adhesion measured by iPA does not decrease significantly. The 
assay is specific to P2Y12 inhibitors when ADP is added since platelet adhesion of 
patients on aspirin alone is not significantly different than healthy donors. It is also 
significant that iPA correlates well with established techniques to measure platelet 
function such as LTA and the point of care device VerifyNow
®
.
 
Interestingly, we 
showed that four patients from our cohort (17%) were classified as responders by 
LTA but appeared as non-responders when measured by iPA. This can be explained 
by the fact that iPA measures adhesion of individual platelets. Therefore small 
aggregates could be detected by iPA but may not affect light transmittance 
aggregation by LTA. Moreover, any change in platelet reactivity that is in any way 
modulated by the presence of red blood cells will not be detected by LTA, due to its 
reliance upon PRP, but will be detectable by iPA. 
Additionally, as ADP induced platelet activation is affected by the second generation 
anti-psychotic drug clozapine iPA was used to show ADP inhibition in patients with 
schizophrenia taking clozapine. When ADP was added to the blood sample, platelet 
adhesion in schizophrenic patients taking clozapine was significantly higher than in 
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controls thus showing ADP inhibition. This correlates with previous data showing 
ADP inhibition by clozapine (in vitro) measured by LTA [128]. 
The next finding is related to the detection of bleeding risk in renal failure patients. 
Renal failure patients on haemodialysis taking aspirin have lower basal platelet 
adhesion (no ADP was added) than controls, measured by iPA. As mentioned before 
renal failure patients have a tendency to bleed but the exact mechanism is still 
unknown. In this chapter we have shown that renal failure patients on haemodialysis 
taking aspirin but not on haemodialysis alone or on peritoneal dialysis have lower 
platelet adhesion than controls. Since current platelet function test do not predict 
bleeding risk [134] this data is very promising for the development of a new and 
more complete platelet function test. Nevertheless a low basal platelet adhesion in 
iPA is probably a sign of platelet dysfunction but it is still unknown whether this low 
adhesion is due to platelets aggregation during the iPA procedure or to low binding 
affinity to fibrinogen. Therefore further iPA studies should be made in these patients 
with agonist addition to investigate whether they have normal aggregation response. 
To summarise, we have shown that iPA is a platelet function specific assay able to 
detect P2Y12 inhibition in vivo. It correlates well with standard techniques such as 
LTA and Verifynow®. Furthermore iPA can be used to detect platelet dysfunction 
associated with uremic patients. 
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 Chapter 6 
Conclusions and Discussion 
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We have developed and improved a whole-blood platelet adhesion assay named iPA 
that reliably and specifically detects anti-platelet drug effects from in-vivo drug 
therapy using digital counting of surface-adhered individual platelets. iPA directly 
measures platelet function by assaying the binding of statistically meaningful 
number of individual platelets to printed spots of a protein array. This method has 
the potential to personalize and improve the efficacy of anti-platelet therapy. The 
speed and ease of the iPA assay are facilitated by binding of platelets in pre-defined 
locations identified by fluorescent staining. The quantification process is a simple 
binary assessment of each protein dot being either occupied or empty. In this thesis, 
we focused on an assay based upon the binding of platelets to 6-μm fibrinogen spots. 
First we showed that αIIbβ3 inhibition by the drug abciximab can be measured by 
iPA and is well correlated with flow cytometry though flow cytometry requires 
several additional steps. In light of this, iPA is a proof of concept for detection of the 
anti-platelet effects of abciximab. These results were detected rapidly and showed a 
significant difference before and after therapy. As a proof of concept this assay or 
other assays that detect such an effect may be important in managing post-operative 
bleeding and guiding therapy in patients undergoing percutaneous cardiac 
intervention. The proof of concept assay developed in this thesis could form the basis 
for larger clinical trials that could comprehensively address this issue. 
Secondly we showed that iPA can detect the effect of other anti-platelet agents by 
adding a specific platelet agonist to the blood sample. The ability of iPA to detect the 
effect of P2Y12 inhibitors relies on the addition of ADP to whole blood samples 
which reduces the number of single (non-aggregated) platelets. Our results indicate 
that the higher the extent of platelet aggregation induced by ADP then the lower the 
number of free single platelets available for binding to the iPA device. Inhibition of 
platelet aggregation with the drug cangrelor (an ADP-receptor inhibitor) gives 
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adhesion values analogous to those from unactivated samples. This implies 
simultaneously that platelets are not aggregating and that they are binding normally 
to fibrinogen. In comparison, LTA, can say only that they do or do not aggregate. 
Thus, iPA directly measures platelet function in the form of basal adhesion while at 
the same time, can indirectly measure platelet aggregation. Since basal adhesion 
alone can be a sign of both platelet hyper and hypo-function. In iPA, low platelet 
adhesion when no agonist is added can be a sign of both platelet hyper and hypo-
function but in any case indicates platelet dysfunction. Nevertheless it is still 
unknown whether this low adhesion is due to platelet aggregation during the iPA 
procedure or to low binding affinity to fibrinogen. Therefore further iPA studies 
should be made in these patients with agonist addition to investigate whether they 
have normal aggregation response. 
Arguably, this is a more biologically informative combination than measuring 
aggregation alone as iPA can be carried out simultaneously on multiple proteins to 
achieve a degree of specificity unavailable from generic aggregation. However, since 
aggregation assays are well developed iPA can offer a complementary assessment of 
specifically selected platelet-protein interactions.  
Based on the above we determined the ability of iPA to detect P2Y12 inhibition in 
comparison with light transmission aggregometry (LTA) and the aggregation-based 
VerifyNow
®
 system. While there is good correlation between the three assays when 
measuring the in-vitro effect of cangrelor on a blood sample from a healthy donor, 
iPA displays a broader measurement range than either LTA or VerifyNow
®
. Our 
results show that iPA is sensitive to cangrelor concentrations over which LTA and 
VerifyNow® are essentially unresponsive (saturated), namely from 0.1 – 1.0 μM of 
cangrelor. Specifically, the percentage of platelet adhesion measured by iPA in 
samples with 0.1, 0.5, and 1.0 μM cangrelor was 26 ± 3%, 33 ± 0.5%, and 43 ± 3%, 
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respectively. The fact that LTA and VerifyNow
®
 become saturated and iPA does not 
could be reasonably explained by the use of 6-μm protein dots, which measure any 
significant decrease in the number of single platelets available to bind without 
requiring a particular aggregation threshold to be surpassed as VerifyNow
®
 and LTA 
do. This correlates with previous reports which show that VerifyNow
®
 does not 
detect differences in platelet response at high levels of P2Y12 inhibition [81]. 
Additionally, we found that when ADP was added to iPA for detection of P2Y12 
inhibition the assay was unaffected by aspirin, a drug very commonly administered 
to cardiovascular patients often in conjunction with P2Y12 inhibitors. The presence 
of aspirin, but its lack of influence on platelet adhesion means that there is a specific 
detection of P2Y12 inhibition when using ADP.  
A main purpose of platelet function testing is to determine if a patient is responsive 
to the administered anti-platelet therapy. Despite being often cited as the gold 
standard for measurement of platelet function, LTA in fact only enables inference of 
platelet function from changes in their tendency to form many-platelet aggregates. 
Previous studies with LTA showed that patients taking clopidogrel and who had an 
aggregation value higher than 64% following sample treatment with 20 μM ADP 
were defined to be non-responsive to anti-platelet therapy [83]. Based on the LTA 
cut-off point, 11 patients in our cohort of 23 were considered non-responsive to 
clopidogrel therapy because the addition of ADP resulted in comparatively high 
aggregation. These same 11 patients were also identified as non-responders to 
clopidogrel therapy with iPA by defining a percentage of adhesion value of 36% as 
the cut-off point. Interestingly, however, we showed that using 36% as the cut-off 
point, 4 patients were classified as responders by LTA but measured as non-
responders when processed by iPA. This discrepancy can be explained by the 
difference in what the two techniques measure: for these 4 patients, LTA indicates 
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that the addition of ADP to their PRP samples does not provide the higher level of 
aggregation typically associated with lack of response to clopidogrel; but iPA 
indicates their whole blood has a change in availability of single platelets upon 
adding ADP that is typical of non-responders. This is due to the ability of iPA to 
analyze platelets individually while in comparison, LTA examines formation of light 
transmission when platelets aggregate. Small aggregates involving as few as two or 
three platelets could indicate undesirable residual platelet activity, not fully 
eliminated by clopidogrel, that will be measured by iPA but may not affect light 
transmittance in platelet aggregation measured by LTA. Moreover, any change in 
platelet activity that is in any way modulated by the presence of red blood cells will 
not be detected by LTA either, due to its reliance upon PRP, but will be detectable 
by iPA. Our results suggest that iPA may detect patients who are non-responders to 
clopidogrel but are undetected by LTA. This accounted for approximately 17 % of 
the patients involved in this study. 
Due to its ability to measure single platelet adhesion, iPA can detect the effect of 
other platelet inhibitors by adding their counter specific agonists. For instance we 
have shown that iPA can detect the aspirin effect by adding AA to the blood.  
We have described how iPA can detect anti-platelet drug responses in vivo in 
coronary artery disease patients. However, this is not the only potential use of the 
assay. It was also shown that iPA can be used to detect platelet dysfunction in renal 
failure patients taking aspirin. Platelet adhesion in patients on haemodialysis taking 
aspirin is significantly lower than healthy controls and patients on hemodialisis who 
are not taking aspirin, an observation that could indicate bleeding risk in these 
patients. It is known that uremic patients have a tendency to bleed [130]. Our results 
suggest that platelet function and bleeding risk in renal failure patients should be 
examined before prescribing anti-platelet medication. There is no platelet function 
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test available which can detect simultaneously bleeding risk and anti-platelets drugs. 
Therefore this could be the first test that combines both detection of bleeding risk 
and anti-platelet drug effect. 
In addition, the second generation anti-psychotic drug clozapine has been shown to 
inhibit ADP induced aggregation in vitro [128]. We have shown how this effect can 
be detected by iPA in vivo. The mechanism of drug detection is similar to that used 
for the ADP inhibitors; clozapine inhibits the ability of ADP to decrease platelet 
binding in iPA. These results suggest that clozapine may have anti-thrombotic effects 
and may partly reduce prothrombotic risk described in schizophrenic patients. The 
mechanism of this phenomenon is unknown and requires further studies. 
In conclusion iPA is a novel platelet function assay that sensitively and specifically 
detects anti-platelet drug responses in vivo. It requires only a fraction of a surface, 
smaller than one square millimeter. This would make it easy to integrate into a 
microfluidic device that uses small volumes of blood for simultaneous measurements 
of multiple receptor/protein combinations under controlled shear conditions, an 
extremely important parameter in platelet function. The methodology presented here 
to quantify cell adhesion and cell-protein interactions should prove applicable to a 
wide range of cell adhesion processes and systems. 
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Future directions 
 
In this thesis it has been shown how iPA detects the effect of several anti-platelet 
drugs by measuring a combination of adhesion and aggregation to a fibrinogen array.  
The iPA assay ability of detection of anti-platelet drugs has been shown to correlate 
very good with both LTA and VerifyNow in vitro and ex vivo. Nevertheless it would 
be very interesting to compare iPA ability to detect anti-platelet drugs with levels of 
receptor inhibition which could be done by flow cytometry [81]. P2Y12 inhibition 
can be measured using radiolabelled ADP (33P-2MeS-ADP) which only binds to 
P2Y12 when this is not occupied by the inhibitor. Comparing P2Y12 inhibition by 
flow cytometry and iPA would determine the accuracy of iPA to detect anti-platelet 
drugs. 
On the other hand the cut-off point for detection of drug effect in iPA has been 
determined by comparison with a different platelet function test, namely LTA. 
Nevertheless ideally this cut-off point should be set by comparing with patients 
outcomes (major adverse cardiovascular events over time). A patient cohort should 
be recruited and iPA should be measured and the cardiovascular events recorded 
then the optimal cut-off point should be adjusted. This experiment would determine 
the ability of iPA to predict cardiovascular events (predictive value).     
Furthermore iPA has been shown to detect a decrease in platelet adhesion in renal 
failure patients taking aspirin who are known to have a higher risk of bleeding. In 
this thesis I present basal platelet adhesion to fibrinogen measured by iPA but 
indirect platelet aggregation was not measures in these patients. For future 
experiments would be interesting to measure platelet aggregation in these patients 
together with adhesion to further investigate whether the decrease in adhesion is due 
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to platelet hypo function or to platelet aggregation. Thereafter the ability of iPA to 
detect bleeding risk could be investigated. 
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